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ABSTRACT 
The contributions and interactions of the vasopressin (AVP) and endothelin (ET) 
systems in the hypertensive state were investigated in deoxycorticosterone acetate 
@OCA)-salt hypertensive rats. The first part of the thesis reports on studies designed to 
assess the hernodynamic contriiution of ET and to compare the responses of a non- 
selective ET antagonist to a selective ETA antagonist, The wond part of the thesis 
reports os experiments designed to evaluate the involvement of Vl receptors and the 
reciprocal role of AVP and ET to the maintenance of bIood pressure (BP). The third part 
of the thesis reports on studies designed to quantifL the contriiution of ET to the 
responses evoked by AVP. All !he experiments in this thesk were carried out in 
chronically instrumented DOCA-salt hypertensive and SHAM control rats implanted 
with telemetry devices for recording of BP and Transonic flowprobes for recording of 
cardiac output (CO). Total peripheral resistance (TPR) was calculated fiom the BP and 
CO recordings. 
In the t3st study, bosentan, a non-selective ET antagonist, and BMS-182874, a 
selective ETAantagonist, were injected into both DOCA-saIt hypertensive and SHAM 
rats intravenously. In contrast to SHAM tats, bosentan and BMS-182874 lowered BP 
and TPR dramatically in DOCA-salt hypertensive rats. Both antagonists increased CO. 
The magnitude and time-course of the hernodynamic effects of bosentan and BMS- 
182874 were similar. These d t s  suggest that the cmtriiution of ET to the 
maintenance of high BP in this hypertensive animal is exerted at the Level of the 
resistance vesseIs. This contn'bution can be accounted for by its effects on ETA receptors. 
In the second study, [~(CHZ);, ~ - ~ e - ~ y ? , A r g ~ ] - v a r o ~ s i n ,  a VI antagonist, 
was administered in the absence and presence of bosentan. Administtation of the VI 
receptor antagonist done failed to lower BP and TPR in DOCA-salt hypertensive rats. 
However, the V1 antagonist did lower BP and TPR when the ET system had been 
blocked. in other experiments, bosentan was administered in the absence and presence of 
the VI antagonist. Bosentan done reduced BP and TPR, but the respollses to bosentan 
were exaggerated when V1 receptors were blocked. These results indicate that AVP 
contributes to the maintenance of hypertension via its VL receptor-mediated 
vasoconstrictor effects. It also reveals the reciprocal or redundant nature of the AVP and 
ET systems in regulating hernodynamics in DOCA-salt hypertensive rats. 
In the third study, a range of doses of AVP was infused intravenously in DOCA- 
salt hypertensive and SHAM rats before or after bosentan treatment. The increases in BP 
and TPR elicited by AVP were blunted by bosentan both in DOCA-salt hypertensive and 
SHAM rats. The effect of bosentan was more pronounced in the hypertensive rats. In 
contrast to AVP, responses to Ang 11 were not modxed by bosentan. These findings 
provide direct evidence that ET contributes to the hernodynamic responses of AVP. This 
contriiution to the pressor activity of AVP is exerted at the level of the resistance 
function of the circulation. 
In conclusion, the results of this thesis demonstrate the involvement of both the 
ET and AVP systems and their reciprocal or redundant relationship in the control of 
systemic hernodynamics in the DOCA-salt model of hypertension, The results aIso 
demonstrate a contniution of ET to the pressor activity of AVP in this model. 
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1. Introduction 
Evidence has suggested that both the vasopressin (AVP) system and endothelin 
(ET) system pIay important roles in the development and maintenance of 
deoxycorticosterone acetate (D0CA)-salt hypertension. Both AVP and ET exert 
vasoconstrictor and hypertrophic effects on cardiovascular tissue. [a this introduction, 
effects of AVP, ET and their interaction are reviewed in normotensive and hypertensive 
animals. In addition, the pathophysiology of DOCA-salt hypertension and the roles of 
AVP and ET in this hypertension are reviewed 
1.1 Crrdiovascuhr Eff- of AVP and ET in Normal Animals 
1.1.1 Effect of AVP 
Arginine vasopressin (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-GlyNH2 ) is a
polypeptide containing nine amino acids. It is secreted by the posterior pituitary gland, 
also cded the neuro-hypophysis, which is composed mainIy of glial-Iike cells called 
pinricytes (Guyton and Hall, 1996). However, the pituicytes do not secrete hormones; 
rather they act as a supporting smcture for large numbers of t e m i d  nerve fibers and 
t e rmid  nerve endings arising h m  nerve tracts in the supraoptic and paraventricular 
nuclei of the hypothalamus. These tmcts pass to the posterior pituitary gland through the 
pituitary stalk (hypophysiaI stalk). The nerve endings contain many secretory granules 
which secrete the two posterior pituitary hormones, vasopressin and oxytocin. AVP is 
mainly synthesized in the cell bodies of the supraoptic nuclei, whereas oxytocin is 
synthesized in the paraventricular nuclei. Then they are transported in combination with 
carrier proteins called neurophysins down to the nerve endings in the posterior pituitary 
gland. 
The release of AVP from the posterior pituitary occurs in response to a .  action 
potential. The generation of electrid signals and subsequent hormond release occurs in 
response to synaptic release of neuroactive agents, such as acetylcholine and ET (see 
section 1.2.3. l), h m  nerve terminals in the hypothalamus and the posterior pituitary. 
When nerve impulses are transmitted downward along the fibers h m  the supraoptic or 
paraventricular nuclei, AVP is immediately released fbm the secretory granules in the 
nerve endings and absorbed into adjacent capillaries. Both the neurophysin and the 
hormone are secreted together, but because they are only loosely bound to each other, 
AVP separates almost immediately. Neurophysin has no known fimction after leaving 
the nerve terminals. 
The historical development of AVP can be traced back to the last century. As 
reviewed by Cowley and Liard (Cowley and Liard, 1987), Oliver and Schafer first 
observed in 1895 that pituitary gland extracts caused a sustained increase in bIcxxi 
pressure (BP) when they were injected into anesthetized dogs (Oliver and Shafer, 1895). 
Thee years later, Howell confirmed these observations and demonstrated that the 
pressor principle resided in extracts of the posterior lobe of the pituitary gIand (Howell, 
1898). The antidiuretic actions of AVP were discovered almost 20 years later. In 1913 
two physicians, Farini and Von den Velden independently demonstrated the successful 
treatment of patients with diabetes insipidus with posterior pituitary extracts (Farini, 
19 13; Von den Velden, 1913). SubsequentIy, in 1924 Starling and Verney demonstrated 
the antidiuretic effects of posterior pituitq extracts on the isolated kidney (Starling and 
Vemey, 1924). Because its pressor actions required amounts far in excess of those 
required for maximal antidiuretic activities (McCommghey et al. 1999), the antidiuretic 
role of AVP became the predominant aspect of interest. 
Nevertheless, the cardiovascular activity of AVP was revealed over a number of 
years. In 1922, Krogh showed that hypophysectomy was associated with vasodilation in 
the frog, suggesting a pituitary substance may play a role in cardiovascuIar regulation 
(Krogh, 1922). In addition, Frieden and Keller found dogs with diabetes insipidus were 
more susceptiile to hemorrhage than normal dogs, suggesting the AVP might have an 
important role in the control of BP during pathological conditions, such as hemonhage 
(Frieden and Keller, 1954). in 1956, Wagner and Braunwald demonstrated that much 
lower doses of AVP were required to exert vasoconstrictor responses in patients with 
autonomic nervous system indiciency (Wagner and Bramwald, 1956). Unfortunately, 
many of these eartier obsefvatiom were overhoked due to the overwhelming interest in 
the renal actions of AW. 
The cardiovascular and vascular smooth muscle actions of AVP were studied 
more intensively following several developments: the characterization and synthesis of 
AVP by Du Vigneaud in 1954, which indicated that the vasopressor and antidiuretic 
properties were in the same peptide @u Vigneaud et aL 1954); the development of a 
sensitive and specific radio imrnunoassay for measuring the concentration of AVP in 
plasma, urine and tissue (Miller aud Moses, 1969; Mohring and Mobring, 1975); and the 
development of AVP analogues which selectively mimicked or antagonized the 
vasoconstrictive or antidiuretic activities of the peptide (Liard, 1988; Manning and 
Sawyer, 1986; Sawyer and Manning, 1988). The physiological range of plasma AVP is 
between 0.3 pg/mI, with water overhydration averaging 20 nVkg body weight, to IeveIs 
between 20 and 30 p g / d  with 48-hour water restriction (Cowley and Barber, 1983). 
These levels can increase to levels exceeding 600 pg/d under certain stressful events, 
such as surgery and hypovolemia (Equivalence between units used in Literature for AVP: 
1 hole=1.084 pg-0.434 pU; molecular weight of AVP: 1084). 
AVP exerts its major biological actions through activation of VI- and V2 
receptors. (Jard, 1998; Mayinger and Hensen, 1999). The V1 receptor is mainly 
expressed in the liver and vascular smooth muscle ceIIs where it mediates glycogenoiytic 
and vasoconstrictor responses. The VI receptor is coupled to G protein Gql Activation 
of this complex evokes increases in the activities of phospholipases C (PLC), D and At, 
production of inositol1,4,5-triphosphate (IP3) and diacylglycerol @G), activation of 
protein kinase C (PKC), mobilization of intracellular caIcium and the influx of 
extracellular cdcium via a receptoraperated ca2+ channel. The Vz receptor is expesed 
in the r e d  medulla, where it mediates the antidimtic &cct of AVP. The V2 receptor is 
coupled to G protein Gs. Activation of this compkx evokes increases in adenylyl 
cyclase activity, prodproduction of cyclic AMP (CAMP) and activation of protein kinase A 
(PKA). This signaI transduction pathway mediates the insertion of water chaMeIs into 
the Luminal mhce  of the renal collecting tubule cells. More recently, another AVP 
receptor was demonstrated and named as V3 or Vlb receptor (as opposed to the Vt 
receptor, which has been reclassified as the Via receptor) (Nakamura et 4. 1999; Jard et 
at. 1986). It is mainly expressed in coreicotmphic cells in adenohypophysis md induces 
ACTH release. 
1.1.1.1 Pressor properties of AVP 
AVP may increase BP via its direct vasocoastrictor actions on vascular smooth 
muscle, antidiuretic actions on kidney and central actions on brain. 
1.1.1.1.1 Vascularactions 
A# evokes vasoconstriction directly via Vt receptors expressed on vascular 
smooth muscle ceh.  Direct observation of blood vessels has allowed investigators to 
evaluate the effective vasoconstrictor concentrations of AVP by measuring the effect of 
the pept..de on lumen diameter. In 1973, A h a  observed the vasoconstriction in rat 
mesenteric arterioles in vivo elicited by topically applying a very low concentration of 
AVP at 10 pgiml, a concentration within the physiological range (Altura, 1973). These 
arterioles were more sensitive to AVP than to angiotensin II (Ang II). The threshold for 
Ang I1 was three times greater than that for AVP, which suggested that AVP might be 
one of the most potent circulating vasoconstrictors found at that time (AItura and AItura, 
1977; AItura and AItura, IW).  SimilarIy, rat mesenteric arterioIes were three to four 
orders of magnitude more sensitive to AVP than to epinephrine or norepinephrine (NE). 
Even rat aorta exhibited greater sensitivity to AVP than to Ang II (Altura and Altura, 
1977; Altm, 1978). More recently, AVP bas been reported to induce potent mitogenic 
and hypertrophic effects on vascular smooth muscle (Tabara et al. 1997; Serradeil-Le 
Gal et al. 1995). These effects were sigdicantly inhibited by a Vi receptor antagonist, 
suggesting the hyperpiastic and hypertrophic actions of AVP are mainly mediated via its 
VI receptors on vascular smooth muscle cells. 
The vasoconstrictor effects are not homogeneous. The most sensitive vessels to 
AVP are the mesenteric, skeletal muscle, skia and carotid arteries (Altura, 1975; Schmid 
and Patel, 1987), while hepatic arteries and veins are moderately sensitive. The 
sensitivity of vascular smooth muscle inincreases with decreasing vessel diameter. In 
1995, Chen et al. reported that the sensitivity and maximal response to AVP was 
increased in small artery compared to conduit vesseI: the rank order was tail artery > 
mesenteric artery > aorta (Chen et al. 1995a). However, the responses to AVP on 
coronary and cerebral arteries and on the pulmonary vascular bed are contmversiai 
( A h a  and Altura, 1984). The peptide has been demonstrated to induce vasoconstriction 
and dilation of cerebral arteries (Lluch et aI. 1984; Onoue et al. 1994; Armstead, 1996), 
no effect or dilation in pulmonary vasculature (Garcia-Viialon et al. 1996; Walker et al. 
1989) and constriction and dilation of coronary arteries (Garcia-Villalon et d. 19%; 
Katusic et aI. 1984; Okamura et al. 1999). The reasons for these differences are 
unknown, and they may be dated to among animal species and among 
experimental proem as we11 as to the role of the endothetiurn in vascular reactivity. 
The AVP-induced vasodiIatation is dependent on the integrity of the endothelium and is 
associated with the release of nitric oxide (NO) (Katusic et al. 1984; Katusic, 1992; 
Okamura et al. 1999). 
The pressor sensitivity to AVP is significantly different among species (Cowley 
and Liard, 1987). When the autonomic nerve system (ANS)  is functional, humans seem 
to be the least sensitive, followed by dogs and then rats. With an intact ANS, a rise of 
only 10 mmt-Ig BP was observed in humans at infusion rates of 100 ng/kg/min of AVP, 
whereas BP rose ftom 15-25 mmHg in dogs and rats at rates of only 10 ngkg/min, 
indicating a 10-fold difference in pressor sensitivity. 
In summary, AVP is a potent vasoconstrictor of resistance vessels h m  some of 
the major vascular beds. However, its effects are heterogeneous among various regional 
vascular beds and among species, 
1 . l .  1.1.2 Effect on baroreflexes 
AVP is a more potent vasoconstrictor of microvesseIs than Ang II. However, Ang 
II produces more potent pressor responses than AVP with an intact baroreceptor reflex 
arc (Schmid et al. 1985a). Studies have suggested that the pressor effects of AVP are 
strongly bdfered by baroreflexes and the ANS. In 1974, Cowley et aI. reported the 
substantial increases in AVP pressor sensitivity in conscious dogs with the sinomrtic 
bmreceptor denemation (SAD) (CowIey a al. 1974). The threshold sensitivity was 
reduced nearly 1 l-fold and the pressor sensitivity was 60-100 fold above normal 
conscious dogs, *on of physiological lev& of AVP (0.2-2.0 mU/kg/min) caused an 
average increase in BP of33 mmHg in SAD dogs compared with an increase of 5 mmHg 
in n o d  dogs. By comparison, only 3 fold increases in pressor sensitivity were 
observed with infusions of NE. A similar enhancement of AVP pressor sensitivity was 
observed in conscious SAD rabbits (Undesser et al. 1985). These data indicate that AVP 
normally enhances the abiity of the baroreflexes to buffer an AVP-induced rise of 
arterial pressure. Furthermore, in total areflexic dogs in which all CNS structures were 
removed, AVP induced an 8000-fold increase in pressor sensitivity when compared to 
normal conscious dogs (Cowley et al. 1974). Similarly, in humans with primary 
autonomic insufficiency, pressor responses to AVP were enhanced at least 50-fold 
compared to normal individuals, whereas the responses to both NE and Ang II were 
enhanced only 2-10 times (Mohring et al. 1980). Thus, the pressor responses to AVP are 
enhanced in both baroreceptor denervation or areflexic states in humans and dogs. 
A different picture is seen in rats. AVP exerted only a 5-fold enhancement of 
pressor sensitivity, an enhancement which was similar to that for phenylephrine (PE) (5 
fold) or Ang I1 (6 fold) in sinoaortic barodenervated rats (Webb et al. 1986). However, in 
1987 Osbom et al. showed that the pressor sensitivity to AVP was markedly enhanced by 
ganglionic blockade, in contrast to Ang II in rats. The ANS was blocked by 
hexamethonium and methscopolamine and BP was supported by continuous idision of 
NE. Under these conditions, AVP pressor sensitivity was increased 60 fold compared 
with a 2-8 fold enhancement to Ang I& which was similar to the responses of Ang II in 
SAD rats (Webb et al. 1986). The differences in AVP pressor sensitivity between SAD 
rats and rats with total autonomic blockade are the resuIt of "nonbaroreflex" reduction of 
sympathetic tone by AVP. Rats in which the afferent limb of the baroreflex is blocked, 
but in which e f f '  sympathetic @ways are intact (such as SAD tats), have some 
capacity to offset the vasoconstrictor actions of AVP by withdrawal of sympathetic 
tone. Pharmacological btockade of these efferent pathways (such as ganglionic blockade 
rats) removes this 'honbmrefl exn buffering mechanism and d t s  in a firrther 
potentiation of the pressor activity of AVP. 
Direct evidence for AVP modification of overall baroreflex function was tested 
by Cowley and his coUeagues in 1984 using carotid sinus perfusion methods in 
anesthetized dogs (Cowley et al. 1984a). In these studies, the carotid sinus regions of 
both left and right intemal carotid arteries were isolated from the rest of the systemic 
circulation, and carotid sinus presswe was controlled independently of systemic arterial 
pressure. Changes in aortic ptessure and cardiac output were measured in response to 
step changes of bIood pressure within the isolated carotid region. In contrast to elevated 
plasma levels of h g  II, they o b m d  that elevated plasma AVP concentrations (htn 
5 1-455 pglml) enhanced reflex controI of arkrial pressure during decmses (60-105 
mmHg) but not increases from the equilibrium point of carotid sinus pressure. The ratio 
of the change of aortic pressure to the change of carotid sinus pressure represents the 
strength of the reflex response and is defined as the 'bopen-lwp feedback gainn of the 
reflex, which was enhanced about 2 fold by the eIwated piasma AVP concentrations. 
Elevation of aortic pressure expected fiom the vasoconstrictor actions of AVP were 
buffered by a second major mechanism, namely reductions in cardiac output (CO). 
Suppression of CO did not occur in conscious SAD dogs (Montani et aI. 2980). These 
data indicate that AVP enhances the ability of the carotid reflexes to normalize deneases 
of BP through changes in TPR, but buffers a rise in pressure from its own 
vasoconstrictor properties by initiating a fall of CO. 
Changes in heart rate (HR) are often used as another index of baroreceptor 
activation. In conscious dogs, the bradycardic responses with AVP administration were 
greater than for equipressor doses of methoxamine, Ang II and PE (Hendrickx et al. 
1976; Robinson, 1986). Enhanced bradycardic responses associated with AVP have also 
been demonstrated in rabbits (Undesser ct aI. 1985) and rats patar et al. 1985; Patel, 
199 1). Therefore, the reflex-induced bradycardia observed with administration of AVP 
appears at least to be consistent between species and is far greater than that observed 
with other vasoconstrictor agents. Thus, as judged from change in HR, these data clearly 
suggest that AVP can augment baroreflexes in a specific way. 
Recording of peripheral sympathetic nerve activity provides direct evidence on 
the interaction of AVP with baroreflex control. Undesser et al. recorded renal 
sympathetic nerve activity (RSNA) in conscious rabbits during equipressor doses of 
AVP and PE (Undesser et al. 1985). They found that the decrease in RSNA was much 
greater with AVP. The effect of the decrease in RSNA by AVP was significantly 
attenuated by vagotomy and Sm, indicating that the reduction of RSNA was dependent 
on afferent baroreceptor activity. Similarfy, in anesthetized rabbits, AVP was found to 
facilitate reflex inhibition of Iumbar sympathetic nerve activity (LSNA) (Sharabi et al. 
1985). These results contrast with those obtained with Ang lI, which produced less 
change in LSNA than PE for similar pressor responses (Guo and Abboud, 1984). Thus, 
at least in rabbits, baroreflex inhi'bition of peripheral sympathetic nerve activity is 
enhanced during AVP admhkmtion and inhibited with Ang II administration. 
However, in anesthetized rats, AVP did not facilitate baroreflex inhibition of LSNA 
(Sharabi et al. 1985), but it did have such an effect on HR (Schmid et al. 198%). Thus, 
AVP appears to facilitate reflex inhibition of HR and peripheral sympathetic activity, but 
species differences are evident 
AVP may facilitate baroreflex activity at several sites. In 1985, Schmid et aI. 
used the isolated carotid sinus preparation of the rabbit to investigate the effects of AVP 
on carotid baroreceptor-induced inhibition of LSNA (Schmid et al. 1985a). They found 
that this peptide enhanced reflexes both when it was restricted to the region of the carotid 
sinus and when it was excIuded h m  this region. They suggested that the latter effect 
was due to an action on brain. In I98 1,  L i d  et al. reported that infusions of AVP into 
the canine vertebral artery appeared to elicit greater reflex decreases in HR than similar 
intravenous infusions, suggesting that AVP may act on sites within the area of perfirsion 
of the vertebral artery, such as the area postrema (AP) (Liard et al. 1981). 
The AP is located on the dorsal surface of the fourth ventricle of the medulla, and 
it lacks a blood-brain barrier (Wiilocki and Leduc, 1952). Therefore, it wouId be readily 
accessible to blood borne AVP. The AP is rich in AVP receptors (Phillips et al. t 988b; 
Phillips et al. 1988a). The enhancement of sensitivity of baroretlexes by AVP was absent 
in AP-lesioned animals (Undesm et al. 1985; Peuler et al. 1990). In AF-Iesioned rats 
and rabbits, the differences in reflex bradycafdic resporesponses to AVP vs PE disappeared In 
animals in which the cell bodies of the AP had been destroyed by injection of an 
excitotoxin or by AVP antagonists, the AVP-induced enhancement of baroreflexes was 
bIocked (Cox et aI. 1990; Stebbins et al. 1998). Many neurons originating in the AP 
project into the nucleus tractus solitarius (NTS), where nerve endings of baroreceptor 
affaents also terminate. Therefore, activation of AP neurons by AVP, either h m  
microinjections into the AP or by intravenous infusions, alters the response of some NTS 
neurons to baroreflex stimulation (Qu et al. 1997). 
The AVP-induced enhancement of baroreflex function appears to be mediated by 
VI receptors in the AP (Hasser and Bishop, 1990; Stebbins et al. 1998). In 1990, Hasser 
and Bishop reported that the ability of circulating AVP to augment baroreflex inhibition 
of RSNA compared to PE was abolished by microinjection of a Vr antagonist into the 
AP in anesthetized rabbits (Hasser and Bishop, 1990). Similarly, Stebbins et al. 
observed the microinjection of a VI antagonist into the AP attenuated AVP enhanced 
href l ex  inhibition in anesthetized cats (Stebbins et al. 1998). However, the role of Vl 
receptors in enhancement of baroreflexes by AVP in rats is less clear. In anesthetized 
rats, microinjection of AVP into the AP caused an increase in BP. The increased BP by 
AVP was attenuated by the microinjection of a V1 antagonist into this area o w e s  et al. 
1993; Smith et al. 1994). In addition, V2 receptors may also be involved in the AVP- 
induced enhancement of baroreflexes in rats. In the Brattleboro rat, a r;lt homozygous for 
diabetes insipidus @I), the impaired baroreflex function was restored to normal by 
intravenous injection of DDAVP, a V2 receptor ago& (Imai et d. 1983). Similarly, 
intravenous &ion of a V2 antagonist shifted the baroreflex curve @dse intend vs. 
BP) to a lower sensitivity, while a V1 antagonist shifted the curve to higher sensitivity in 
conscious rats (Unger et al. 1986b). Additionally, microinjection of DDAVP c b d y  into 
the AP had a depressor effect in anesthetized rats (Lowes et al. 1993). Taken together, 
it has been concluded that AVP can sensitize the baroreflex by acting on both VI and V2 
receptors accessible fiom the blood and there may be species differences in term of 
receptor involvement. 
In summary, AVP appears to enhance baroreflex sensitivity to a greater extent 
than other pressor agents. It interacts with baroreceptors (afferent), the AP (CNS) or 
efferent limbs of the reflex arc to facilitate baroreflex inhibition of autonomic nervous 
system (ANS) function to buffer its cardiovascular effects. Species differences may exist 
with respect to baroreflex modulation by AVP and to the receptor systems involved. 
I. 1.1.1.3 Effects on cardiac output and total peripheral resistance 
As elucidated to above, the unimpressive pressor effects of AVP are buffered by 
another major mechanism, i.e. a decrease in CO (Cowley et al. 1984a). indeed, plasma 
concentrations required to increase BP exceed 50 to 100 pghl  in man and dogs, 
concentrations which are well above the physiological range (Aylward et al. 1986; 
Montani et al. 1980). Rats do appear to be more sensitive to the pressor effects of AVP, 
and marked elevations of BP have been reported to occur at plasma concentration of 20 
pgkg (Datar et al. 1985; Osborn et al. 1987). 
In contrast to changes in BP, marked decreases of CO occur at plasma levels of 
AVP well within the physiological range. In 1980, Montani et al. reported that 
elevations in the circulating levels of AVP in conscious dogs to only 4 2  pg/ml fiom a 
control value of 2.1 pg/ml were associated with signiscant 8% decreases in CO and 12% 
increases in TPR, even though there were no changes in BP (Montani et al. 1980). 
These results demonstrated clearly that plasma concentrations of A W  within the 
physiological range can significantly decrease CO and increase systemic vascular 
resistance. With increments in the concenmtions of the peptide to about 71 pgtrnl, a 
57% increase in TPR was accompanied by a 24% decrease in CO resulting in only an 8 
mmHg increase in BP. Similarly, in humans, an increased plasma A W  level by I3 pg/d 
from a control of 5 pg/d  resulted in a 15% decrease in CO and a 20% increase in TPR 
without marked changes in BP (Ebert et al. 1986). Because BP is the product of CO and 
TPR, the vasoconstrictor effects of the peptide can conceivably be buffered directly at 
the level of vascular smooth muscle via changes in TPR or indirectly via changes in CO. 
Rats appear to be the least sensitive to these effects, since elevation of the plasma levels 
of AVP to approximately 30 pg/ml evoked a 23% rise in TPR, but only a 9% fall in CO, 
resulting in a 13 mmHg increase in BP in conscious rats (Osborn et al. 1987). But the 
highest dose of AVP increased BP 34%, whereas TPR was increased 150% and CO was 
decreased 42% in rats. Similar results have been demonstrated in rats and dogs where 
endogenous AVP secretion has been stimulated by dehydration or hypertonic saline 
administration (Charocopos et al. 1982; Montani et aI. 1980; Tipayamontri et al. 1987). 
In the pathophysiological range, AVP induced increases in both BP and TPR, but the 
elevations in BP are not proportional to the rises in TPR Five and 17% increases in BP 
were associated with 54 and 94% increases in TPR in dogs (Montani et al. 1980; Pang et 
al. 1979). 
Direct comparisons of the hernodynamic effects of AVP and Ang II have been 
studied in conscious dogs. Heyndrickx et al. reported that for 25% elevations in BP, CO 
fell by 44% with AVP, 16% with methoxamine (MX) and 8% with Ang II, while TPR 
rose by 153% with AVP, 61% with MX and 48% with Ang II in conscious dogs 
(Hendrickx et al. 1976). Even in rats, CO fell and TPR rose greater with AVP than Ang 
II for comparable increases of BP (Osbom et al. 1987). Therefore, AVP appears to exert 
greater effects on CO and TPR for a given increase in BP than other vasoconstrictors. 
Baroreflex control of capacitance function may contriiute to the MI of CO 
induced by AVP. The decreases in CO associated with the elevation of AVP in the 
animal with intact reflexes were markedly reduced in the denesvated dogs (Montani et al. 
1980). Moreover, ganglionic blockade also attenuated the CO responses to AVP (FuJii 
and Vatner, 1987). The AVP -induced fall of CO was nearIy absent in barodenervated 
dogs, despite substantial elevations of TPR. Cowley and Barber analyzed these results 
and indicated that the unexpectedly d influence of AVP on CO in the badenervated 
state during graded increases in TPR could be explained by the hydraulic charactenstl . . C 
of the parallel nature of the vessels of the systemic circdation (Cowley and Barber, 
1983). Parallel flow beds can exhibit increases of TPR with no decrease in CO if one of 
the parallel beds has a greater vascular compliance (skin or splanchnic) than another. 
However, in conscious rats, the impairment of reflex fimction by either gaa@on 
blockade or SAD did not attenuate the d m  in CO but potentiated the increases in 
both BP and TPR associated with AVP -tion (Osborn et al. 1987; Webb et aI. 
1986). 
AVP could have negative inotropic actions on heart. In conscious dogs, AVP 
depressed left ventricular perfomance at plasma concentrations of 15 pg/ml. This 
negative inotmpic effect was present after autonomic blockade and was reversed by a 
VI antagonist (Cheng et al. 1993). However, in rats, AVP exerted coronary 
vasoconstriction and positive inotmpic effects on heart at concentrations between 50 and 
100 pg/ml and myocardial depression at higher concentrations (Walker et al. 1988; Boyle 
and Segal, 1986). By using the isolated heart p a i o n  technique, Grafet al. fomd that 
AVP at high concentrations of 120 - 2500 pg/d  caused myocardial depression indirectly 
by reducing coronary flow during constant perfUsion pressure in guinea pig, and it had no 
direct myocardial effect because when perhion was maintained by constant coronary 
flow, myocardial function was maintained ((3rd et al. 1997). In view of these 
considerations. it is unlikely that a direct negative inotropic action of AVP contriiutes 
substantially to the fall of CO. 
The cardiovascular effects of AVP could be buffered by decreases in CO that 
were mediated via changes in capacitance function of a highly compliant vascular bed. 
Changes in capacitance have marked effects on venous return and thus, play an 
important role in regulating CO (Greenway and h u t .  1986). Indeed, AVP infusions 
were accompanied by a decrease in venous ~ t u m  in dogs (Tipayamontri et d. 1987; 
Emerson, 1966) and pigs (Welt and R u t h ,  1991). In 1990, Martin and McNeiIl directly 
assessed the effects of AVP on capacitance function in anesthetized cats by draining 
blood from superior and inferior venae cava into an external reservoir and then retuning 
blood to the right atrium at a constant rate (Martin and McNeiil, 1990). In contrast to 
Ang I1 and NE, AVP was associated with concentrationdependent increases in whole 
body capacitance, and this increase was accounted for by a reflex increase in unstressed 
vascular volume but not systemic compliance, supporting the theory advanced by 
Cowley and Barber (1983). However, AVP failed to change mean circulatory filling 
pressure and the pressure gradient for venous retum in rats (Pang and Tabrizchi, 1986; 
Hernandez et al. 1994). Regardless of the precise mechanism, it is clear that CO is 
dramatically decreased during AVP infirsion and that these changes in CO may attenuate 
the pressor effects of the peptide. 
In summary, AVP evokes a marked till in CO compared to equipressor doses of 
other vasoconstrictors, especially in dogs and humans. The fall in CO appears to be 
mediated by enhanced cardiovascular reflexes, largely at the level of the capacitance 
vessds although a negative inompic effect on heart caunot be excluded. In rats, the fa11 
in CO is less and the mechanism of the fidI in CO has not been determined. 
1.1.1.1.4 Effects on kidney 
FunctionaI studies have shown that the water retaining properties of AVP are 
mainly mediated via V2 receptors located in the collecting tubule and the thick ascending 
limb of HenIe's loop. The major effect of AVP on the kidney is to increase water, but 
not urea, permeability of the late distal tubules and collecting ducts in renal cortex and 
outer medulla (Valtin, 1987). However, AVP dws increase urea as well as water 
permeability of the collecting duct that lies within the inner medulla (Jamison and Kriz, 
1982; Sands et al. 1987). Coasequently, urea can now diffbse out cif the inner medullary 
coUecting duct into the interstitiurn more effivefy because its concentration within the 
tubuIar fluid was raised by the abstraction of water fiom the proximal portions of the 
collecting duct. Aside h m  these effects, AVP also enhances the reabsorption of NaC1 
from the thick ascending limbs of HenIe that runs through the outer medulla (Hebert et 
d. 1981). As the result of NaCl and urea reabsorption in outer and inner medulla, the 
peptide enhaaces the buildup of the corticopapillary gradient, which is critical for the 
antidiuretic effect of AVP at the collecting duct 
The discovery of the aquapin (AQP) M y  of water channels has greatly 
improved the understanding of how water crosses epithelial cells (Marples et aI. 1999). 
AQPs are a family of transmembrane chaanel proteins that serve to regulate 
transepithelial water reabsorption and body fluid homeostasis. AQP 1, the first AQP to be 
characterized (Age et al. 1993), is involved in water movement of the proximal tubule, 
whereas AQP2, AQP3 and AQP4 are found in the collecting duct AQP2 is the AVP- 
regulated water channel that is expressed exclusively in the principal cells of colIecting 
duct (Agre et al. 1995). AVP binds to Vz receptors in the basolateral membrane of 
collecting duct principal cells and induces the insertion of AQP2 h m  a store within 
intracellular vesicles into the apical pIasma membrane of the cells, with CAMP as the 
second messenger (Marpies et al. 1999). This action of AVP results in the enhancement 
of water reabsorption in the collecting duct. 
In dogs, prolonged administration of AVP for 2-3 weeks increased BP with fixed 
water intake (Smith et al. 1979), but BP remained normal when water intake was 
servocontmlled (Cowley et aI. I984b). These &dings indicate that the plasma IeveIs of 
AVP in the range of 15-25 pg!ml, as measured in these studies, produces hypertension 
more related to expansion of body fluid volume than to any vasoconstrictor effect. This 
is supported by the observation that continuous infusion of 6DAW, a V2 receptor 
agonist, and hypotonic fluid induced an increase in BP in rats (Gross et al. 1982). 
Recently, six lines of evidence supporting the causative role of the kidney in 
hypertension have been reviewed by CowIey and Roman (Cowley and Roman, 1996) 
The importance of d decreases of blood flow to the renal medulla was emphasized in 
the development and maintenance of hypertension. Chronic infusion of AVP failed to 
induce sustained hypertension. ta conerast to AVP, chronic intravenous bibion of a 
selective Vt receptor ago& induced sustained hypertension in the absence of water 
retention in conscious rats (Cowley et al. 1994). This effect could be prevented if a 
selective VI receptor antagonist was administered simdtaneously into the renal medulla 
(Szczepanska-Sadowska et al. 1994). Therefore, the renal medulla appears to be a critical 
site for VI receptor-mediated hypertensive effects. Indeed, chronic infusion of a VI 
receptor agonist directly into renal medullary interstitial space resulted in a sustained 
decrease in renal medullary blood flow and increase in BP in conscious instrumented rats 
(Cowley et al. 1998). Together with the fact that the renal medullary vasculature is quite 
sensitive to small elevations of plasma AVP (6-12 pglml) (Franchini and Cowley, I996), 
it is reasonable to postulate that V1 receptor induced hypertension is at Ieast in part 
dated to its vasoconsuictor efkct on renal meduiIary va~culature~ 
In summary, the major effects of AVP on the kidney are to increase the insextion 
of AQP;! into the apicai membrane of the principal ceU of collecting ducts via its V2 
receptor, and then to enhance water permeability in collecting ducts. The vasoconsErictor 
effect of Vl receptors on renal medullary vasculame, which induces the reduction of 
medullary flow and then the decreases in renal interstitial hydrostatic pressure and Na 
excretion, contributes at least in part to its hypertensive action. 
1.1.1.1.5 Effects on brain 
In addition to its central actions on memory formation, fever and social 
recognition (Alescio-Lautier et al. 1993), AVP exerts its cardiovascular effects centrally 
as well. Central infusions of AVP into certain areas, such as the nucleus of the solitary 
tract (NST) (Matsuguchi et al. 1982), the locus coeruleus (Berecek et al. 1984b) and the 
ventrolateral medulIa (Andreatta-Van-Leyen et d. 1990), produce increases in BP and 
HR. Similar pressor responses were also observed in AVP-deficient Brattleboro rats, 
indicating that the pressor responses could not be accounted for by activation of 
endogenous brain AVP or neurohypopbysial release of the hormone (Nussey et al. 1984). 
The pressor effect of centrally administered AVP was blocked by central but not 
peripheral administration of a Vt receptor antagonist (Berecek et al. I984a; Unger et al. 
1986b). 
In contrast to its peripheral actions, the central pressor effects of AVP appear to 
be associated with an enhancement of sympathetic activity, such as increases in HR, 
efferent splanchnic nerve activity and renal nerve activity (Rohmeiss et al. 1986). These 
responses were attenuated by intravenous injection of the a-adrenoceptor antagonist, 
phentoIamine (Rohmeiss et al. 1986; Riphagen and Pittman, 1989), demonstrating that 
the central pressor effects of AVP are mediated at [east in part by the activation of 
sympathetic activity. Moreover, AVP supptesses baroreflexes in normotensive animals 
centrally. Administration of a VI receptor antagonist centrally increased the sensitivity of 
baroreflexes (Unger et al. 1986a). By contrast, intravenous infusion of the VI receptor 
antagonist had no effect on baroreflexes. These results suggest that AVP inhibits 
baroreflexes in the brain via its V1 receptors, which are not accessible from the 
peripheral circulation. 
In summary, the effects of AVP in certain areas of the brain are associated with 
increases in BP and HR. These actions are mediated by an increase in sympathetic nerve 
activity and a decrease in baroreflex sensitivity. 
1.1.1.2 Depressor properties of A W  
In contrast to the pressor effects of AVP, there is mounting evidence that AVP 
may exert depressor responses in animals and humans through direct vasodilatation and 
effects on kidney and brain. The recent discovery of novel selective hypotensive 
vasopressin peptides has provided additional evidence supporting a depressor function 
(Chan et al. 1998). 
1.1.1.2.1 Effects on vasculature 
AVP induced vasodilatation has been reported both in d s  and humans, and 
it is not clear which receptor subtype, VI, VI or a distinctly different receptor subtype, 
mediates the vasodilating effects of AVP. In kt, bth VI and V2 receptors autagonists 
have been shown to inhiiit the vasodilating action. In humans, Hirsch et al. and 
Emaizumi et al. reported that AVP in pharmacological doses caused vasodilation of 
vessels in the forearm (Hirsch et al. 1989; hainmi et al. 1 W), and this vasodilation 
could be inhibited by a V2 receptor anragon& Further experiments showed that this 
vasodilator effect was abolished by Nw-nitro-L aqjnhe-methyl ester (L-NAME), a
nitric oxide synthetase (NOS) idhibitor, indicating the effect depends on the release of 
NO (Tagawa et d. 1993). In dog, L i d  observed a vasodilator effect of the systemic 
vascdatute induced by dDAVP, a Vz receptor agonist, and this effect was antagonized 
by L-NAME (Liard, 1994). A similar effect was also found in the rat aorta (Yamada et 
ai. 1993). Intrarenal infusion of AVP (Naitoh et aI. 1993) or AVP with a V1 w-"ptor 
antagonist (Aki et al. 1994) induced renal vasodilatation in dogs, and these effects were 
reduced by a V2 receptor antagonist. Furthennore, this renal vasodilatation was also 
suppressed by a NOS inhibitor (Haynes et al. 1993). On the other hand, NO-releasing 
activity of AVP is also reportedly mediated by V1 receptor stimulation. Katusic et al. 
showed that Vl receptor stimulation relaxed the dog brain stem artery (Katusic, 1992). 
The relaxation was inhi'bited by NG-monomethyl-L-arginine (L-NMMA). In addition, 
AVP increased the production of cGMP, a second messenger of NO, in cultured porcine 
aortic endothelid cells through V, receptor stimulation (Schini et al. 1990). Furthermore, 
Waker et al. reported a V1 receptor-mediated vasodilatation in the isolated rat lung 
during hypoxia (Walker et al. 1989). The controversy of AVP receptor subtype-inducing 
vasodilatation may be due to species differences and differences among arteries and 
regional beds. Briefly, AVP can induce vasodilatation and this effect may be NO-release 
dependent. 
RecentIy, Chan et al. discovered four novel selective hypotensive AVP peptides 
(Chan et d. 1998), which could elicit a marked f d  in BP in anesthetized rats. This effect 
was independent of the periphd autonomic, bradykinin and prostaglandin system, and 
was not mediated by the known cIassical AVPIOT receptors. NO did not appear to have 
an important role in their vasodepressor action. These results indicate that there may 
exist an unknown AVP receptor subtype or a new receptor outside the AVP receptor 
f d y  for these novel hypotensive AVP peptides. The findings also suggest another 
mechanism for AVP-induced vasodilatation aside fiom the release of NO. 
In summary, besides its vasoconstrictor properties, AVP can induce 
vasodilatation under certain conditions through Vt or V2 receptor. This vasodilator e f f i  
appears to be related to the release of NO. Additionally, a novel receptor subtype may 
evoke a NO independent vasodilation. 
1.1.1 2.2 Effects on kidney 
Despite the fact that AVP is an antidiuretic and antinatriureric hormone in vitro, 
it does induce natriuresis when administered to animals for a long period in v i v a  Studies 
done by Hall et al. showed that prolonged @ion of AVP normally produced water 
retention and increased urinary osmolarity during the first four days. After that, however, 
urine volume and osmolarity returned to normal despite the continued infusion of AVP 
(Hall et al. 1986). This phenomenon is often referred to as "escapen h m  the antidiuretic 
action of AVP. Moreover, AVP administration in conscious unrestrained rats increased 
sodium excretion (Wang and McNeill, 1994), despite reductions in lrrine flow lgrimble 
et al. 1988; Lote et al. 1989). After immunoneutralization of AVP, a posterior pituitary 
extract did not induce natriuresis in anesthetized saline Ioaded rats, as compared to 
untreated extract (Ponec et al. 199 I), indicating that AVP may be the natriuretic 
substauce in the posterior pituitary extract. The mechanism of the natriuresis induced by 
AVP is not clear. SeveraI possible explanations have been proposed, including pressure 
natriuresis (Hall et al. 1986), decreases in renin secretion @iBona, 1982; Smith et al. 
1979), increases in circulating atria1 natriuretic peptide (ANP) (Manning et al. 1985) and 
increases in PG secretion (Schuster et d. 1984). In any case, regardless of the 
mechanism, AVP does have an effect to induce natriuresis in animals. 
The relationship between the bIood flow in the renal medulla, which lacks 
autoregulation (Roman et ai. 1988; Mattson et al. 1993), and hypertension has been 
studied intensively by Cowley and his co-workers recently. In contrast to V1 receptor 
agonists (see section 1.1.1.1.4). chronic intravenous infusion of AVP failed to induced 
sustained hypertension in conscious rats (Cowley et al. 1994). Furthermore, chronic 
infusion of a Vt receptor agonist, but not AVP, directly into the renal medullary 
interstitial space induced a sustained decrease in renal medullary blood flow and an 
increase in BP in conscious instrumented rats (Cowley et al. 1998). These results 
indicate that some component of AVP nlay counteract its VI receptor effects on the renal 
medullary vasculature to limit the increase in BP and this component could be due to the 
stimulation of V2 receptors by AVP in rend medulla or some unidentified vasodilator. 
In summary, despite its antidimtic effects, prolonged idision of AVP induces 
natriuresis in animals. In contrast to a Vl receptor agonist, AVP fails to induce 
hypertension when admlnrswed * * directIy into the r e d  medulla, indicating that some 
component of AVP may counteract its V, receptor effect on renal medulla to Iimit BP 
elevation. 
1.1-123 Effects on brain 
It has been well established that central infusion of AVP in certain areas of the 
brain is associated with an elevation of BP and HR (See section 1.1.1.1 S). However, the 
peptide has been reported to lower BP and HR under certain conditions. Hemorrhage, 
which is known to release AVP into the cerebrospinal fluid (CSF) and brain tissue (Ota 
et al. 1994; Szczepanska-Sadowska et al. 1983), induces hypotension and bradycardia in 
normotensive rats. However, this response could be significantly attenuated by infusion 
of a V1 receptor antagonist into the lateral cerebral ventricks (8uddkowski et al. 1996), 
indicating that a central VI receptor system is involved in hypovolemic hypotension and 
bradycardia. Indeed, mild, rapid hemorrhage (1 dl00 g for 30 seconds) induced severe 
bradycardia and hypotension observed in Long-Evans rats, was absent in AVP deficient 
Brattleboro rats (Imai et al. 1W6). Microinjection of AVP into the NTS at low doses (1- 
100 pg) caused a dosedependent decrease in BP and HR in rats, and only high doses (1 - 
10 ng) caused an increase in BP and HR (Sonntag et al. 1990; Brattstrom et al. 1988). 
Moreover, microinjection of AVP into the subfomical organ (SFO) resulted in 
significant decreases in BP; while microinjection of the peptide into the third ventricle 
produced large increases in BP (Smith and Ferguson, 1997). These resuits indicate that 
centrat hypotensive effects of AVP may be related to dose and location. 
In 1983, Ganten et al. deveIoped a new hypertensive model, which was 
established by cmss-breeding SHR-SP with Brattleboro rats (Ganten et al. 1983). Their 
offspring (SHRDI) were hypertensive with undetectable plasma, hypothalamic and 
pituitary gland AVP levels. They conciuded that AVP is not essential for the 
development and maintenance of spontaneous hypertension. However, another 
interpretation is that it is the tend deficiency of AVP that is necessary for the 
hypertensive state. Indeed, BrattIeboro tats are hypertensive compared to control rats 
(Imai et al. 1990). 
In summary, in addition to its central pressor effects, AVP exerts depressor 
actions in brain as well. The depressor actions may be related to dose and location, and 
the deficiency in this system may contribute to the hypertensive state. In addition, central 
AVP also contriiutes to the hypotension and bradycardia induced by hypovolemia. 
1-1.1.2.4 The withdrawal-induced antihypertensive phenomenon 
Cessation of a 3-hour idision of AVP (20 ng/kg/min) induces a large fall in BP 
below pre-infusion basal levels in both SHR and DOCA-salt hypertensive rats, but not in 
control normotensive rats (Chiu and McNeill, 1985; Chiu and McNeill, 1989b; Chiu and 
McNeill, 198%; Wang and McNeilI, 1 994, Balakrishnm and McNeill, 1996; Taiom and 
McNeill, 1997). The response was named the "WithdrawaI-induced antihypertensive 
phenomenon (WAP)". The WAP is relativeIy specific to AVP (Chiu and McNeiII, 1986), 
because equipressor doses of PE or Ang II caused no or much lower f d s  in BP. The f d  
in BP was dramatic (13-17 mmHg recorded by radiotelemetry devices and 30-50 mmHg 
recorded by externalized catheters) and lasted for 5 days (Balakrishnan and McNeill, 
1996). The magnitude of the WAF paralleled the degree of hypertension (Chiu and 
McNeiU, 1989b). Both V1 receptor stimulation and the associated increases in BP were 
required for the phenomenon (Chiu and McNeill, 1987), since the WAP couId be 
abolished by a VI receptor antagonist even when BP was elevated to a similar extent 
with PE or when BP eievation was prevented by pre-treatment with sodium 
nitroprusside. These findings suggest that AVP possesses a blood pressure lowering 
property which is masked by its direct vasoconstrictor properties, and this BP lowering 
proprty in the WAP is mediated by its VI receptors. 
The mechanism of the WAP is not clear yet It may involve an interaction of 
AVP with autonomic function or an effect of AVP on renal function. Chiu and McNeill 
reported the WAP was exaggerated in SHR rats sympathectomized by chronic treatment 
with guanethidine (Chiu and McNeilI, 1995). Moreovery a small drop in BP was dso 
observed in sympathectomized WKY after the withdrawal of AVP. Together with the 
fact that AVP can sensitize baroreflexes and depress sympathetic activity (see section 
1.1 .I. 1.2), these findings indicate that withdrawal of sympathetic activity is a 
contributing factor or a pre-requisite condition for development of the WAP. In other 
experimentsy Wang et d. showed a large natriuresis during the AVP infusion in 
hypertensive rats. Furthermore, replacement of the sodium Iosses that occurred during 
the AVF infusion attenuated the WAP markedly in DOCA-salt hypertensive rats, but not 
in S H R  (Wag and McNeill, 1994), suggesting that sodium Iosses contniute to the WAP 
in the DOCA-salt model but not in the SHR Recently, Tatchum-Taiom and McNeill 
tested the role of NO in the WAP, and found that WAP could be produced in Nw-nitro-L- 
arginine (L-NNA), a NOS inhiitor, induced hypertension (Talom and McNd, 1997). 
L-NNA failed to prevent the WAP, and chronic treatment with L - m e ,  a NO 
precursor, did not exaggerate the WAP in SHR. These findings w e s t  that the NO 
pathway is not essential to the WAP at least in SHR rats. Functional studies have showed 
that the WAP was due mainly to decreases in CO and not to changes in TPR 
(Balakrishnan and McNeill, 1996). 
In summary, cessation of a prolonged infirsion of A W  is associated with a 
dramatic and prolonged fall in BP in hypertensive animals (SHR, DOCA-salt and L- 
NNA induced hypertensive rats) but not in nomotensive rats. A W  appears to have a 
hypotensive property which counteracts its well-known blood pressure elevating 
properties. 
1.12. Effects of ET 
In 1988, endothelin- 1 (ET- 1 ) was isolated and identified fmm the supernatant of 
cultured porcine aortic endothelid cetts as a potent vasoconstrictor and pressor substance 
(Yanagisawa et al. 1988). This peptide has a molecular weight of 2492. It consists of a 
21 -amino acid with two intrachain disdfide bridges which occur at fixed positions 
between residues 1 and IS, and 3 and 1 1, a hydrophobic tail and a terminal tryptophan 
residue. ET- 1 is present in many m a d  species, including humans. Two additional 
human ET isopeptides, ET-2 and ET-3, are encoded by separate genes (Inoue et al. 
1989). These isofom of ET share the identical chemical features. The three ETs also 
have structural and functional similarities to the d o t o x i n s ,  a family ofisopeptides 
isdated h r n  the venom of the snake Anactaspis engaddensis, which suggests a possible 
common evolutionary origin (KIoog and Sokolovsky, 1989). 
The discovery of ET came h m  the identification of an endothelidderived 
constricting factor 0. In 1984, two abstracts were published, one by Agricola et al. 
and another by O'Brien and M c M w ~ q  (Agricoh et al. 1984; OBrien and McMurtry, 
1984). These abstracts reported the discovery of a vasoconstrictor substance secreted 
h m  endothelid cells. In the following year, a paper by Hickey et al. (Hickey et al. 1985) 
appeared in which they concluded that this substance was a endothelid cellderived 
polypeptide vasoconstrictor, since it was protease-sensitive, and caused a dosedependent 
constrictor response in coronary arteries ifextraceUdar ca2+ was available. This 
vasoconstrictor was insensitive to a and j3 adreneqic, serotonergic, histaminergic and 
cholinergic receptor antagonists, as well as cycIooxygenase and lipoxygenase inhibitors. 
In 1986, Gillespie et al. studied the vasoconstrictor properties and first referred to it as 
"endothelidderived constrictor factor" or "EDCF" (Gillespie et al. 1986). In the 
following year, another relevant paper was published from the same group (O'Brien et al. 
1987), in which they confirmed the polypeptide nature of EDCF and estimated its 
molecular weight to be arouud 3000 daltons. Moreover, they noted that its constrictor 
effect was partially reversed by the calcium antagonist, verapamil. Finally in 1988, 
Yanagisawa et al. succeeded in sequencing this polypeptide from porcine aortic 
endothelid cells and named it as "endothelin" (Yanagisawa et al. 1988). They observed 
its remarkable potency as a vasoconstrictor agent, more potent than that of Ang I1 and 
AVP, making it the most potent mammalian vasoconstrictor polypeptide to be identified 
so far. They also confirmed Hickey's earlier observation relating to the ca2+ dependency 
of the coronary constrictor response and mt their paper by concluding that an influx of 
ca2+ is required for the action of ET. 
The discovery of ET receptors and deveIopmem of receptor antagonists 
accelerated investigation of the physioIogicd and pathophysiological roles of the ETs. 
The development of ETdeficient and ET receptordeficient mice demonstrated the 
crucial roles in normal embryonic development, ET-ldeficient mice have craaiofacial 
and cardiac abnormalities and die of respiratory failure soon after birth (Kurihara et al. 
1994). A deficiency in ETB receptors results in aganglionic megacolon, which resembles 
Hirschsprung's disease in human effenberger et al. 1994). 
1.1.2. I ET biosynthesis and its receptors 
Although vascular endothelial cells are the major source of ET-1, the genes that 
encode the three endothelin isopeptides are expressed in a wide variety of cell types, 
inciuding cardiac rnyocytes, vascular smooth muscle, renal tubuIar epithelium, 
glomenrlar mesangium, glia, the pituitary, macrophages, etc., which suggests that the 
peptides may participate in complex regulatory mechanisms in various organs (Inoue et 
ai. 1989; Sakurai et al. 1991). 
ET isoforms are synthesized from large pre-proforms ( preproET-1: human 212 
amino acids, porcine 203 amino acids) which undergo post-translational processing by 
diiasic amino acid endopeptidases to pro-peptides or big ETs ( Big ET-1: human 38 
amino acids, porcine 39 amino acids) (Yanagisawa et al. 1988; Kid0 et al. 1997). Big ET 
is then cleaved by ET converting enzyme (ECE), a phosphoramidon-sensitive membrane 
bound metalloproteinase (Ohaka et al. 1993), to yield the &A 21-amino acid peptide. 
In vascuiar endothelid cells, ET-I is secreted via the constitutive pathway, and the rate- 
limiting step of its biosynthesis is thought to be at the level of transcription (Yanaghwa 
et al. 1988). The conversion of big ET-I to ET-1 is essential for bio1ogica.I activity, 
because the pressor action of big ET-1 was almost completely inhibited by a relatively 
large dose of phosphoramidon, an inhiitor of ECE (Gardiner et al. 1991). Indeed, ET-1 
is 140-fold more potent as a vasoconstrictor compared to the precursor peptide (Kimura 
et al. 1989). 
ET-I gene expression in vascular endothelial cells is regulated by a variety of 
physical and chemical stimuli. ET-1 mRNA level is increased after treatment of 
endothelial cells with growth factors (Klrrihara et al. 1989), insulin, or with vasoactive 
substances such as NE, Ang II, AVP and bradykinin (Imai et al. 1992). High shear stress 
(25 dynedcm2) decreases ET mRNA lev&, whereas low shear stress (5 dynes/cm2) 
increases its mRNA expression (Malek and Izumo, 1992; Sumpio and Widmann, 1990). 
In contrast, the expression of ET-l mRNA is inhibited by stimuli that act to increase 
inmcellular levels of cGMP, including endotheliumderived relaxing factor (NO), 
prostacyclin, ANP, heparin and adrenomedullin (Emori et al. 1993; imai et al. 1993; 
Kohno et al. 1995). 
ET-induced responses may be divided into two groups: the first group including 
vasoconstriction, bronchoconstriction, uterine smooth muscle contraction and 
stimulation of aldosterone secretion; and the second group including endothelium- 
dependent vasorelaxation and inhribition of piatelet aggregation. These observations 
suggest that at least two distinct ET receptors mediate these pharmacological responses. 
Indeed, two similar but distinct cDNA encoding ET receptors were cbned h m  rats, 
bovine, and humans (Arai et al. 1990; Lin et al. 1991; Sakurai et al. 1990; Sakamoto et 
al. 1991). These receptors can be d&ed into two groups, designated as ETA and &, 
according to the relative binding &hities of the three ET isopeptides for the receptors. 
The order of affinity for the ETA receptor is ET-I> ET-2 > ET-3 while the ETB 
receptor binds to the three peptides with equal f i t y  (Sakmai et al. 1992). ETA 
receptors are present on vascular smooth muscle cells and mediate vasoconstriction and 
proliferation in response to ET-1 (Ohlstein and Douglas, 1993). ETB receptors are 
present on the endothelium and vascuIar smooth muscle ceUs. Endothelid ETB receptors 
mediate endothelial-dependent vasodilation through the release of NO, prostacyclin and 
adrenomedullin, while ETB receptors in vascular smooth muscle cells cause 
vasoconstriction (Jougasaki et al. 1998; Seo and Liischer, 1995). However, ETB receptors 
in resistance arteries undergo rapid desensitization on exposure to either ET-I or ETB 
selective agonists (Tschudi and LWher, 1994). Interestingly, blockade of ETe receptors, 
but not ETA receptors, increases plasma concentrations of ET-1 and ET-3, and prolongs 
the biological half-life of exogenous [I--ET-1 (L6ffler et ai. 1993; Fukuroda et al. 
1994). The increase in ET-1 does not affect concentrations of big ET-1 and C-terminal 
fragments (Plumpton et al. 1996; Ldffler et d. 1993), c o d m h g  that the increase is 
mediated by displacement of ET-1 h m  receptors rather than through generation. These 
studies indicate that ETB receptors play an important role in the ctearance of ET in 
circulation. 
Both ETA and ETB receptors may be coupled to PLC via a GTP-binding protein 
(Badr et al. 1989). Activation of PLC causes phosphatidyhositol hydrolysis, rapid 
formation of IP3 and DG. IP3 stimulates the release of caz' h m  intracelluIar stores. The 
application of ET-1 to arterial smooth muscle cek  causes a rapid transient increase in 
[&Ti and a subsequent sustained increase in [Ca2']i (~imo~lson a d Dunn, 1990). The 
iaitid transient [ca27i response is not dependent on the pewace of e x t d  ca2+ and 
is the result of IP3-induced mobilization of caZC h m  intracellular stores. In contrast, the 
sustained increase of [ca27i appears to be due to an influx of extracellular ~ a *  through 
either dihydmpyridim-sensitive voltagedependent cak channels (Goto et d. 1989) or 
receptor-operated cation c b e l s  that are insensitive to dihydropyridine (Iwamuro et al. 
1998). In addition to the increase in [&Ti, ET receptor activation causes activation of 
PLA2 and PLD and changes in amchidonic acid metabolism (Rubanyi and PolokoE, 
1994). The activation of PLD appears to contribute to sustained DG accumulation, which 
may lead to prolonged activation of PKC. In vascular smooth muscle and cardiac muscle, 
a change in intracellular pH (alkalization) is also induced via stimulation of Na* - IT 
exchange, which seems to be a consequence of PKC activation. 
In summary, ET isofom are synthesized h m  Iarge pre-profonns to pro- 
peptides or big ETs, and then cleaved by ET converting enzyme (ECE) to the final 2 1- 
amino acid peptide. There are two ET receptors, ETA receptor and ETB receptors, ETA 
and ETB receptors on vascular smooth muscle cells mediate vasoconstriction, while 
endothelid ETB receptors mediate vaSodil8tatio~ The main signal transduction pathways 
of ET-1 are G-protein-mediated activation of PLC, leading to formation of IP3 and DG, 
and the subsequent increase in ra27i by kilitation of ca2+ influx and mobilization of 
intracellular ca2+. 
1. L 2.2 Vascular actions of ET-I 
Circulating concentrations of ET-like immunoreactivity in venous plasma are in 
the range 1-10 pmoYL in healthy subjects (Sumki et aI. 1989; Miyauchi et al. 1991). 
This immunoreactivity comprises big ET-I( about 60%), ET-I (about 30%) and ET-3 
(about 10%). ET-2 has not been detected in human plasma. Circulating concentrations of 
ET-1 are lower than those which cause vascular contraction in vitro and in vivo . 
However, cultured endothelial cells secrete substantially more ET-I towards the adjacent 
vascular smooth muscle than they do luminally (Yoshimoto et al. 1991). Thus, ET-I 
appears to be primarily a locally acting paracrine a d o r  autocrine substance rather than a 
circulating endocrine hormone, In addition, ET-I is rapidly cleared fiom the circulation 
after bolus intravenous injection with a biological half life of about 1 min, although its 
pressor effects are sustained for up to 60 min (Sirvio et al. 1990; Vierhapper et d. 1990). 
A large proportion of the cleatance of ET-1 appears to occur through receptor binding 
and then internalization. 
Intravenous ET-I infusion produces a transient vasodilatation and hypotensive 
response, followed by a sustained vasoconstriction and pressor response lasting for at 
least 60 mi.. The transient vasodilatation is reIated to activation of ETB receptors, while 
the prolonged vasoconstriction is related largely to activation of ETA receptors. ET-I 
causes sustained contraction of conduit arteries, with a potency 10-foId higher than those 
of other constrictors (Yaagkam et ai. 1988). The coronary and renal vascular beds in 
animals are most sensitive to the vasoconstrictor eff'ects of systemic ET-I (Clozd and 
ClozeI, 1989). The mesesteric bed also vasoconsaicts in response to systemic ET-I, 
whereas the hindquarters ske1etal muscle bed exhiiits little constriction (Han et al. 
1989). These differences among beds may be related to differences in distn'bution of 
constrictor (ETA and ETB) and dilator receptors (ETB). 
The ETs stimdate generation of NO by vascular endothelial cells ( S d  et al. 
1991; De Nucci et al. 1988).The transient early vasodilator actions of the ETs are 
attenuated by nitric oxide synthase inhibitors. More relevant physiologically is that NO 
synthase inhibitors potentiate the constrictor and pressor effects of ET-I, suggesting that 
there is an autocrine feedback mechanism modulating vasoconstriction in response to ET 
by stimulation of the endothelial generation of NO. In addition, ET-I also increases 
generation of prostacyclin by cultured endothelid cells (Sufllld et aI. 1991) and 
cyclooxygenase inhibitors potentiate ET-1 induced constriction (De Nucci et al. I988), 
suggesting that vasodilator prostagIandins play a similar modulator role. However, 
venoconstriction to ET-I in humans is potentiated by cyclooxygenase inhibition, but not 
by NOS inhibition, indicating that prostanoids alone modulate the effects of ET-1 on 
veins (Haynes and Webb, 1993). These endothelial effects of ET-I that increase 
generation of vasodilators appear to be mediated by its ETe receptors. 
The physiological roles of ET-l in maintenance of vascular tone and BP have 
been studied by using ET-I deficient mice and ET-1 antagonists. Mice with one ET-1 
gene deleted have slightly higher BP than controIs, despite their lower circulating ET-1 
(Kurihara et aI. 1994). However, there is evidence that the elevation of BP in this model 
is due to sympatho-adrenal ovexactivity caused by hypoxia secondary to abnormalities in 
faciaI/phaqngeal development (Webb et al. 1998). Now it is believed that the best way 
to address the physioIogicaI roIe of endogenous ET-I is to examine the hemodynamic 
effects of drugs that selectively block the generation or actions of ET-I. Although it is 
widely recognized that ET-I does regulate BP under physiological conditions, the 
relative contributions of ETA and ETB receptors is still a matter of debate. 
There is controversy regarding non-selective or selective ETA antagonists on 
vascular tone and BP in normotensive animals. Some investigators showed that non- 
selective (TAK-044) or selective (FRl393 I7 and BQ123) ETA receptor antagonists have 
slight but significant hypotensive effects on BP in normotensive subjects or animals 
(Haynes et aI. 1996; Fujita et al. 1995; Bigaud and Pelton, 1992; Pollock et aI. 1993), but 
others could aot repeat these results with FR 1393 17 and BQ123 (Sogabe et al. 1993; 
Bad et al. 1992). Recently, we reported that both a non-selective ET receptor 
antagonist, bosentan, and a selective ETA receptor antagonist, BMS-182874, failed to 
lower BP in conscious normotensive rats (Balakrishnan et al. 19%; Yu et al. 1998). 
Although ET does not appear essential to maintain 8 P  in the normotensive animal, one 
cannot excIude a contniutive role of ET because blockade of one control system 
typically activates other compensatory systems to maintain vascular tone (McNeill, 
1983). Indeed, local blockade of forearm resistance vessels with the ETA receptor 
antagonist, BQ123, or the non-selective ET receptor antagonist, TAK-044, caused slow- 
onset forearm vasudilatation (Haynes and Webb, 1994; Haynes et al. 1996), supporting a 
physioIogical role of ET-1 in maintenance of vascular tone. Taken together, these data 
suggest that endogenously generated ET-1 may play a role in maintenance of vascular 
tone via ETA receptors. 
However, GeIlai et d has reported that in contrast to a non-selective ET receptor 
antagonist or a seIective ETA receptor antagonist, an ETa receptor antagonist induced 
increases in BP and decreases in renal blood flow in nonnotensive rats (Gellai et al. 
1996), indicating that the predominant role of endogenous ET-1 in norrnotensive animals 
is vasodilatation via ETB receptors. S i  hypertensive effects were found with another 
ETB receptor antagonist, A192621 (Webb et al. 1998). Thus, mder physiological 
conditions it appears that endogenous ET-1 primarily evokes vasodilation and natriuresis 
through endothelid and renal ETB receptors. In addition, intra-arterid infusion of the 
ETB receptor antagonist, BQ-788, produced a sustained vasoconstriction in humans and 
opposed the vasodiIator action of BQ-123 (Verhaar et al. 1998). The kidney is rich in 
ETe receptors that attenuate tubdar reabsorption of sodium and lead to natriuresis 
(Terada et al. 1992; Kohan and Hughes, 1993; Kohan, 1993). Lack of these renal ETB 
receptors in ETB knockout mice and rats causes sensitivity to salt and hypertension that 
is not reversible with blockade of ETA receptors (Webb et aI. 1998). The vasoconstrictor 
effects of ETB receptor antagonists would be consistent with blockade of endothelid ETs 
receptormediated formation of NO. However, it is worth remembering that ETe 
antagonists increase concentrations of ET-1 by blocking clearance receptors (LBffler et 
al. 1993; Fukuroda et al. 1994) and this phenomenon codd aIso account for the pressor 
effects of blockade of ETe receptors. Indeed, there is evidence that the pressor effects of 
ETB receptor antagonism are present even when formation of NO is inhibited and that 
these effects can be blocked by a ETA -tor antagonist (Gratton et d. 1997). 
In summary, endogenous ET-I plays a physioIogicaI role in control of vascular 
tone and blood pressure. However, the overall vascular eE&s depend on the balance of 
ETA-mediated and ETB-medhkd effects- Activation of vascular smooth muscte ETA 
receptors causes vasocoostriction and tends to elevate BP, while stimulation of 
endothelid and renal ETB receptors promotes vasodilation and natriuresis and tends to 
decrease BP. 
I. 1.2.3 Renal actions of ET-I 
ET-I has two main direct actions on the kidney, renal vasoconstriction and 
natriuresis. ET-1 contracts afferent and efferent arterioles equally and thus reduces both 
renal pIasma flow and glomerdar fiItration rate (Lopez-Farre et al. 1989; King et al. 
1989). In addition, there is substantial production of ET-1 by the inner medullary 
collecting duct cells (KO& 1993), and renal tubular epithelial ceUs have a high density 
of ET receptors, mainly of the ETa subtype (Terada et al. 1992). Several lines of 
evidence suggest that this locally produced ET-1 plays an important role in modulation 
of renal excretion of sodium and water. ET-1 inhiits tubular Na'/K' -ATPase activity in 
the proximd tubule and collecting duct to block reabsorption of sodium (Zeidel et al. 
1989). Furthermore, ET-1 inhibits the effects of AVP in the collecting duct to block 
reabsorption of water (Oishi et al. 1991). The CAMP response of inner medullary 
collecting duct cells to AVP is potentiated in the presence of specific ET-1 antiserum 
(Kohan and Hughes, 1993), suggesting that endogenous production of ET-I tonically 
inhibits responses to AVP. indeed, ET-1 generation in renal tubuIe is reduced by an 
increase in osmolarity in vih.0 and by volume depletion in vivo (Kohan and Padilla, 
1993; Michel et al. 1993), and the number of ET receptors in glomeruli and tubules of 
voIumedepleted rats is greater than normal (MicheI et al. 1993). These tubular effects 
also occur with ETB receptor agonists and are not blocked by the E L  receptor antagonist 
BQ-123, suggesting that they are mediated by ETB receptors (Kohan et al. 1993; 
Yukimura et al. 1994). The hypothesis that ETB receptors are involved is also supported 
by the finding that ETB knockout mice have hypertension secondary to renal retention of 
sodium (Webb et al. 1998). 
In summary, locally generated ET-1 plays a physiological role in regulating 
transport of salt and water by inhi'biting N~'/K' -~TPase activity and the effects of AVP. 
The ET- l-induced natriuresis and diuresis are activated via ETB receptors. 
1.2 Effects of AVP and ET-1 in DOCAISalt Hypertensive Rats 
Rat models of hypertension can be divided into primary and secondary groups. 
As reviewed by Pinto et al. (Pinto et al. I998), primary hypertensive models can be 
subdivided into genetic, including SHR, Dahl-salt sensitive and transgenic rats, and 
environmental, including stress-induced hypertensive rats. Secondary hypertensive 
models can be induced by manipulating endocrine function, such DOCA-salt, or by 
manipulating rend function, such as 2K1C hypertensive rats. The fitst animal model of 
hypertension was developed when Harry Goldblatt clipped the renal artery of a dog 
(2K1 C) and produced a secondary form of hypertension. 
Transgenic techniques provide a tool to generate animals that differ from the 
wild-type, either by introducing foreign genes (transgenic animals) or by specific 
mutations of genes (knockat animals). By introducing a mouse Ren-2 gene, the 
TGR(rnRen-2)27 rat is characterized as a renin-angiotensin system dependent 
hypertensive animal with an inverse circadian blood pressure rhythm and severe end- 
organ damage (Witte et al, 1999). However, so far, the SHR is st i l l  the most widely 
used rat model. 
DOCA-salt hypertension can be induced by administration of DOCA in 
combination with a high salt diet and unilateral nephrectomy (Gomez-Sanchez et al. 
1996). The model is characterized as a low renin and volume overload form of 
hypertension. Therefore, it has a different naturaI history and a different response to 
antihypertensives, when compared to the high re& models (SHR, 2K1C and 
TGR(mRen2)27). In fact, this is one of a few hypertensive rat models, in which 
inhibition of the peripheral renin-angiotensin system does not decrease BP and improve 
end-organ changes (Aono et al. 1988). However, diuretics (Cabral et al. 1994), ET 
antagonists (Matsumura et al. 1995) and calcium blockers (Li et al. 1996) are effective 
both with regard to BP and to end-organ changes. End organ damage in this hypertensive 
rat model is reported to include cardiac hypertrophy (Matsumura et at. 1995), renal 
dysfunction (hf5erty et al. 1991) including proteinununa and glomerulosclerosis, and 
impaired endothelium firnction (Kirchner et al. 1993). 
In addition to AVP (see the foUowing section 1.2.I), the brain renia-angiotensin 
system has been impIicated in DOCA-salt hypertension. In 1986, Itaya et al. reported that 
intracerebroventricular infusion of captopril, an ACE inhibitor, attenuated the 
development of hypertension. The prevention of hypertension was accompanied by a 
reduction in plasma AVP in DOCA-saIt hypertension (Itaya et aI. 1986). The decrease in 
plasma AVP was unexpected because the decrease in BP by captopril should have 
evoked a compensatory increase in AVP Ievek This experiment supports the notion that 
the brain renin-angiotensin system is coupled to AVP reIease. A role for the brain renin- 
angiotensin system in DOCA-salt hypertension is finther supported by the fact that Ang 
II receptor density in specific regions of the brain was increased following DOCA 
treatment (Gutkind et al. 1988). 
Aside h m  the central renin-angiotensin system, it is likely that the peripheral 
sympathetic nervous system is involved in the development of DOCA-salt hypertension. 
This notion is supported by the observation that central catecholaminergic depIetion 
attenuated this form of hypertension (Lamprecht et aI. 1977), and that plasma NE and 
catechoIamine level were higher in DOCA-salt treated rats than in normotensive rats 
(Bouvier and Champlain, 1986). 
1.2.1 AVP in DOCA-salt hypertension 
A primary role for AVP in the pathogenesis of DOCA-salt hypertension was first 
suggested by Friedman er al. (Friedman et al. 1960). He found that administration of 
AVP accelerated the development of hypertension in rats treated with DOC& and that 
ablation of the median eminence prevented the development of hypertension. In DOCA- 
salt hypertensive rats, plasma and urine AVP leveIs were reported to be increased 
(Mohring et al. 1977; Crofton et al. 1979), and the severity of hypertension was found to 
be reIated to the pIasma level of AVP. However, AVP binding sites in mesenteric 
vascular bed were signiscantly reduced due to the increases in plasma concentration 
(Lxiviere et al. 1988). Administration of non-selective or sekclive V2 receptor 
antagonists significantly attenuated the development of hypertension (Okada et al. 1995) 
and Iowered BP in the established phase of the MXA-salt hypertension (Hofbauer et al. 
1984; Galatius-J~ensen et al. 1996; Okada et al. 1995). Compelling evidence for a role of 
AVP in the DOCA-sait model arose h m  studies in Brattlebom pi) rats homozygous 
for diabetes insipidus, which lack the ability to synthesize the hormone. These DI rats 
failed to deveIop hypertension when treated with MXA and saIt, but did develop 
hypertension after co-treatment with AVP or dDAVP, a V2 receptor ago& (Crofion et 
al. 1979; Satio and Yajima, 1982). 
However, the role of VI receptors in DOCA-salt hypertensive rats is 
controversial. Pressor responsiveness to AVP has been reported to be increased 
(Matsuguchi and Schmid, 1982; Mimura et al. 1995), unchanged (Bumier et al. 1983), or 
decreased (Filep et al. 1985) in DOCA-salt hypertensive rats compared to its 
normotensive control. Administration of Vt receptor antagonists produced small 
decreases (Hiwatari et al. 1986; Bunell et al. 1994; htengan et al. 1998) or no change in 
BP (Filep et d. 1987; Toba et aI. 1994; Okada et al. 1995). Failure to induce any change 
in BP does not preclude a role of the VI receptor in this hypertensive animal model 
because bloclcade of one system typically activates other systems to regulate BP 
(McNeiII et a!. 1977; McNeill, 1983). Due to the contribution of the ET system in the 
DOCA-salt model (see the following section 1.221, it was postulated that there may be a 
redundant or reciprocal relationship between the AVP and ET systems in maintaining the 
high BP and vascular tone observed in this model. Therefire, aapcll.t of this theszsproject 
was to study the role of VI receptors in the muintenance of hemobynanrics in DOCA-xalt 
hypertensive rats both when the ETsystem was fiurctional and when it wasprevented 
fionl compemaring. 
In summary, there is compelling evidence that circulating AVP is essential for 
the development and maintenance of the hypertensive state in the DOCA-salt 
hypertensive model, although the pressor role of AVP in this model is controversial. 
123 ET-1 in DOCA-salt hypertension 
Several lines of evidence support a role of ET-1 in the development and 
maintenance of hypertension in DOCA-salt hypertensive rats. First, immunoreactive ET- 
1 content is increased in aorta and mesenteric arteries fiom DOCA-salt hypertensive rats 
(Lariviere et al. 1993b; Fujita et al. 1999, but not in those fiom SHR. Second, 
preproET- 1 gene expression in aorta and mesenteric arteries is also increased in DOCA- 
salt hypertensive animals (Lariviere et al. 1993a), suggesting the increased ET-I content 
is secondary to the increased preproET-1 gene expression. Third, in heart, ET-I mRNA 
expression and immunoreactive ET-1 concentration in ventricles h m  DOCA-salt 
hypertensive rats are elevated (Lariviere et al. 1995). Fourth, both non-seIective 
ETA/Eh and selective ETA receptor antagonists have been reported to attenuate the 
deveIopment of hypertension and to decrease BP in established hypertension in this 
model (Li et aI. 1994; Yu et al. 1998; Fujita et al. 1995; Bird et al. 1995). F i  vascular 
hypertrophy and remodeling seen in DOCA-salt hypertensive rats are attenuated with 
chronic treatment of a non-selective ET antagonist (Li et al. 1994). However, ET-1 
production does not seem to contniute to the cardiac hypertrophy seen in this 
hypertensive animal, since the increased Ievel of ET-1 mRNA transcripts was found 
exclusively in endothelid cells of blood vessels and endocardium, but not in myocardial 
cells (Lariviere et d. 1995). In conclusion, all of these observations suggest a role of 
ET-1 in the pathogenesis of hypertension in the DOCA-salt hypertensive model. 
Changes in BP with non-seIective or selective ETA receptor antagonists in 
DOCA-salt hypertensive rats might be due to changes in CO or in total peripheral 
resistance (TPR), and the relative contriiution of these two variables to changes in BP 
induced by ET antagonists have not been reported, Therefore, mt objective of this thesis 
was to adrliess this issue directly by monitoring BP with rudiotelemeny devices and CO 
with ul~amnic transit-timej7uwprobes in COILTC~OUT DOCA-salt hypertensive ruts during 
administration of the non peptide mixed ET receptor antagonist, bosenrrm, and the 
selective ETA receptor antagonist, BMS-182871. 
tu summary, there is convincing evidence supporting a role of ET- t in the 
pathogenesis of hypertension in the DOCA-salt hypertensive model, and this 
involvement of ET appears to be mediated at least in part via ETA receptors. 
1.23 tnteractions between AVP and ET-1 
1.2.3.1 ET on AVP secretion 
ET has been documented to increase AVP and ANP release peripherally and 
. . 
c e n u y .  Intravenous Admlnrstration of ET induced a significant elevation of BP and 
plasma levels of AVP, ANP and renin activity, and dmeases in urine flow and Na 
excretion in dogs (Miller et d. 1989). In addition, ET was also found to be present in the 
central ntmous system, inchding the hypothaIamo-neurohypophysid structures 
(Takaha& et al. 199 1; Nakamura et al. L993). Moreover, ET mRNA and EX receptors 
were distn'buted within brain sites implicated in the central control of cardiovascular 
function and AVP release. Intracerebmventricular infusion of ET-1 at a dose of 3.5 
ng/kg/min evoked increases in BP and plasma levels of AVP and ANP, and decreases in 
urine flow and mimy Na excretion in conscious rats (Yamamoto et al. 1992). These 
increases in BP and plasma ANP, and the decrease in urine flow could be attenuated by 
the peripheral pretreatment of a VI receptor antagonist, suggesting that the increased 
release of AVP contributes to ET central effects. Similarly, Rossi et al. reported that icv 
injection of ET-1 in rats caused increases in BP and plasma IeveIs of AVP (Rossi et al. 
1997). However, it was the enhanced sympathetic outtlow, but not AVP, that contributed 
to the changes in BP eIicited by ET centrally. Regardless of the mechanism of BP 
elevation, ET does increase AVP release by its action peripherally and centrally. 
1.2.3.2 AVP on ET secretion 
Many endogenous physical and chemical stimuli have been reported to stimulate 
the synthesis and release of ET-I from endothelial cells (see section 1.12.1). Among 
them, AVP and Ang II have been reported to stimulate ET-1 secretion from cultured 
bovine carotid artery endothelial cells (Emori et aI. 1991) and human mesangid cells 
(Bakris et al. 1991; Baluis and Re, 2993). The increased release of ET-1 is due mainly to 
the increased expression of prepmET-I mRNA stimulated by AVP and Ang 11 (Imai et 
al. 1992). In perfused mesenteric vascular beds, AVP was showed to increase ET-1 
release (Tomobe et d. I993b). Infasion of AVP, but not Ang II, has been reported to 
increase plasma ET-1 IeveIs in conscious dogs (Emmeluth and Bie, 1992). In tissue 
studies, Chen et al. from our Iab reported that, in contrast to rat aorta, Ang It-induced 
conttslctions of rat mesenteric and tail arteries were endothelium dependent and could 
be partially or completely attenuated by an ETA receptor antagonist in normotensive rats 
(Chen et al. 199%). Similarly, responses of the rabbit aorta to Ang II were attenuated by 
BQ123, an ETA receptor antagonist (Webb et al. 1992). In SHR, Dohi et al. found that 
the contraction of the rat mesentexic artery evoked by NE was potentiated by Ang II. This 
potentiation was endothelium dependent and was prevented by pre-treatment of the 
tissue with phosphoramidon, an ET converting enzyme inhiiitor, or an ET a n t i i y  
(Dohi et al. 1992), indicating the involvement of ET in the Ang II-induced potentiation 
of NE responses. In DOCA-salt hypertensive rats, htengan et d. showed that a VI 
receptor antagonist attenuated the enhanced preproET-1 gene expression in mesenteric 
resistance arteries (Intengan et al. 1998), suggesting ET-I may be involved in part in 
mediating the vascular effects of AVP in DOCA-salt hypertension. 
Although considerable evidence exists at the cellular and tissue levels, there has 
been little effort to quantitj, the contribution of ET-1 to responses evoked by AVP and 
Ang II at the hernodynamic level. Recently hrn our lab, Balakrishnan et al. 
demonstrated that hemdynamic responses to low doses of AVP (1,3 and 10 ngkghin) 
or to low doses of Ang II (3 and 9 ng/kg/min) were blunted by a non peptide mixed ET 
receptor antagonist in SHR, a genetic model of hypertension with high renin IeveIs 
(Balakrishnan et al. 1997; Balakrishnan et al. 19%), indicating the involvement of ET in 
hernodynamic responses to AVP and Ang II in this genetic afiimal model. However, the 
contribution of ET-i to AVP and Ang II at the hernodynamic Ievel in the DOCA-salt 
hypertensive rat, an experimentai hypertensive animal model with low renin Ievel has not 
been reported. In view of the involvement of both AW and ET in the development and 
maintenance of hypertension in this experimental hypertensive animal and in view of 
their interaction in vim and in vivo, it is reasonable to postulate that an ET component 
contributes to the hernodynamic effects of AVP in DOCA-salt hypertensive rats. k, a 
major goal of this thesis project was to qumttifjl rhe contribution of ET-I to the changes 
in BP, CO and TPR induced by A VP in conscious DOCA-salt hypertenrive rats, gl 
recording both jlow and presswe, it was possible to calculate TPR and thus determine if 
any contribution was at the level offactors regulating CO, or at the level offacrors 
regulating the resistance fimction of the circulation For comparison, the responses to 
Ang U were also evaltcmed in this model. .4$mI objective was to determine ifany ET 
component was diflerent in hypertensive and normotensive rats. 
13 Hypothesis and predictions of the working hypotheses 
13.1 Hypothesis 
ET and A VP connibute to the maintenance of hypertension in DOCA-salt 
hypertensive rats by commkting resistance vessels. Part of the increase in resistance 
evoked by A W in this lryperremive animal model is due to an ET- I componem 
133 Working hypotheses and predictions 
I. ET contributes to the mmmntenunce of hypertmon in DOCA-salt hypertensive r m  
via receptor-iked v~oconstriction of resistmce vessels. A prediction of this 
hypothesis is that a non-selective or selective receptor antagonist shouid lower 
II. 
TPR and BP in this hypertensive animal model to a similar extent. To test this 
prediction, the relative contributions of CO and TPR to changes in BP were recorded 
before and after bosentan, a non-selective ET antagonist, or BMS-182874, a 
selective ETA receptor antagonist. 
The contribution of either A VP or ET to the maintenance of BP and vasmlar tone 
may be underestimated when one system is allowed to compensate. A prediction of 
this hypothesis is that the magnitude of the response to an ET receptor antagonist will 
be greater in rats pretreated with a VI receptor antagonist and conversely, the 
response to a VI receptor antagonist will be greater in rats pretreated with an ET 
receptor antagonist. To test this prediction, changes in BP, CO and TPR were 
recorded during the administration of [ ~ ( c H s ~ ,  -~e-~yt',Arg~]-~aso~ressin a VI 
receptor antagonist, before and after the treatment with bosentm In other 
experiments, bosentan was administered before and during the administration of 
[~(CH&', ~ - ~ e - ~ ~ , A r g ~ ] - ~ a s o ~ r e s s i n .  
lII. ET contributes ro the hernodynamic effects of A VP in the DOCQ-salt hypertensive 
rat. A prediction of this hypothesis is that the hemadynamic effects of A W  should 
be attenuated by the blockade of ET receptors in DOCA-sdt hypertmive rats. To 
test this prediction systematically, changes in BP, CO and TPR were monitored 
during administration of AVP More and after bosentan. 
2. Materials and Methods 
2.1 General 
2.1.1 Animals 
All experiments and protocols were performed in accordance with the regulations 
established by the Canadian Council on Animal Care and approved by the animal care 
committee at the University of Saskatchewan. Male Sprague-Dawley (SD) rats were 
purchased h m  Charles River (St. Constant, Quebec) at 6 wk of age and raised in our 
animal quarters under standardized conditions. Some SD rats were first or second 
generation animals bred and raised in our animal quarters. In our final data analysis, 
there was no difference in responses among these rats. 
Rats were selected at 8-10 weeks of age, at which time the right kidney was 
removed through a d o d  flank incision under ether anesthetization. One week later, 
these rats were divided randomly into two groups, DOCA- and SHAM-groups. In the 
DOCA-group, a Silastic strip impqnated with 100 mgkg body wt of DUCA was 
implanted subcutaneously m the midscapdar region. From this point on, these rats were 
given a 0.9% NaCI-0.2% KC1 solution for chinking ad libitum over a 3-week period- 
Under this regimen, this group of rats dewIoped hyperkdon. In the SHAMcontrolled 
group, a DOCA-free Silastic strip was impIanted mbmhneously. Tap water was 
provided as a drinking solution over the next 3 weeks. The SiIastic strip was made in a 
piastic groove model h m  a mixture of medical grade elastomer, silastic curing agent 
(10: 1 wjw) with or without DOCA (10 mg/cm). 
2.13 Chemicals 
The chemicals used in the experiments and their sources are listed as following: 
AVP [(A&-~aso~ressin] h m  Bachem (Tonance, CA); 
Ang II (ocapeptide) h m  Bachem; 
ET- 1 from American Peptide Co. (Sunnyvale, CA); 
 CHI^', ~-~e-~~,Arg~]-~aso~ressin, a VI receptor antagonist, h m  Bachem: 
Sodium pentobarbital h m  MTC pharmaceuticals; 
Deoxycorticosterone Acetate (DOCA) from Sigma (St. Louis, MO), Aldrich Chem. Co. 
(Milw., Wt'), ICN Biomedicals hc.(Aurora, OH); 
0.9% sodium chloride (saline) from ABBOm, 
Medical grade elastomer and s W c  curing agent from DOW CORNING (Midland, h4Q; 
BMS-182874 provided by Brim1 Myers Squibb, NJ; 
Bosentan provided by Dr. M. Clozel (F. Hoffman-La Roche, Basel). 
Stock solutio~~~ of AVP (100 p w ) ,  [~(cHz)~', ~-~e-~y?,Arg~]-vaso~ressin 
(100 pg/ml), Ang II (500 pg!ml) and ET-I (25 pg/ml) were made with Om acetic acid 
and stored at -80 or -20 degree C. Working solutions were then made on the day of the 
experiment by diluting the stock solution with 0.9% saIine. SoIutiom of ET-1 were 
prepared in 1% bovine serum albumia (BSA). BMS-I82874 and bosentan were 
dissolved in 5% NaHCG and steriIe water respectively. 
2.13 Equipment 
Radiotelemetw system 
The components of the radiotdemetry system consisted of the following: 1) a 1 O- 
cm catheter with a 1 cm tip constructed of thin walled tubing which was coated with an 
anti-thrombogenic film. The tip of the catheter had been pre-filled with a viscous gel to 
prevent blood h m  entering the catheter, 2) an implantable capsule (TAl 1PA-C40, Data 
Sciences, St. Paul, MN) which houses a highly stable semiconductor strain gauge sensor 
and a battery powered electronic module to process the information h m  the pressure 
sensor and transmit it from animals to receivers; 3) a receiver (RLA 1020) which detects 
the signal from the implanted transmitter and transmits it to a data acquisition system; 4) 
a barometric pressure reference (C1 IPR) which measures the atmospheric pressure to 
allow for the telemetered absolute pressure (relative to a vacuum) to be converted to a 
gauge pressure (relative to atmospheric pressure); 5) a BCMIOO consolidation matrix 
which mdtiplexes the signals f?om a number of receivers and provides power to the 
telemetry receivers; 6) a data acquisition system (DATAQUEST IV) which accepts data 
from the reference and the receiver, flters cotrupt samples from the incoming data 
stream, converts the telemetered pressure to mmHg, subtracts atmospheric pressure h m  
the telemetered pressure and stores the data for retrieving, plotting and analyzing. 
The catheter material provides for easy insertion, excellent kink resistance and minimal 
vessel irritation. The technique of radiotelemetry system for meamkg BP has been 
validated in our lab and by others (B alakrishnan et al. 1998; B a d  et al. 1993). 
Transonic svstem 
The Transonic system for small animal blood flow measurement consists of a 
bench top electronic flowmeter (T206, Transonic Systems Inc., Ithaca, Ny) and a 
volume flow sensing probe. Using wide beam illumination, two transducers pass 
u l ~ n i c  signals back and forth, intersecting the flowing liquid in upstream and 
downstream directions. The flowmeter derives an accurate measure of the 'transit time' 
it takes for the ultrasound wave to travel fiom one transducer to another. The difference 
between the upstream and domstream integrated transit times is a measure of volume 
flow. The flowprobes can sense volume flow independent of flow velocity. The 2.5 SB 
series flow probe was used for recording CO in these experiments. The signal h m  the 
flowmeter was fed into a pen recorder (model 7P03, Grass Instrument Co. Quincy, MA). 
Others 
Model 7 polygraph, Model TDAF DC driver amplifier fiom Grass lnstument Co.; 
Model 975 infusion pump h r n  Harvard; 
Model 941 infUsionhithdrawal pump fiom Harvard; 
Model 683 small animal ventilator from Harvard; 
Model K-550-G vortex h m  Scientific tudustries hc. 
2.1.4 Miscellaneous 
Micro-renathane tubing: MRE 040 h m  Braintree Scientific; 
TEFLON tubing (0.59 mm ID x 0.83 mm OD and 0.47 mm ID x 0.71 mm OD) 
from B-D; 
Orthocry1 powder and liquid h m  Stratford-Cookson Company, 
Dacron mesh from Small Parts Inc.; 
Silk sutures 4-0 h m  Ethicon. 
23 Surgical p r o d a m  
After 3-week of a DOCA or DOCA-fke treatment, the animals were anesthetized 
with Somotol, (sodium pentobarbital, 50 mgkg) peritoneally. Endomheal intubation 
was performed and the rat was attached to the ventilator. All the following surgeries 
were performed under aseptic conditions. At Ieast a 10-day recovery period was provided 
following the surgery before the animals were used for experimentation. 
22.1 Implantation of the Transonic flowprobe 
A median stexnotomy was performed, and a mimretractor was used to expose 
the thymus and heart. After the pericatdium was opened, the ascending aorta was gently 
separated h m  the pulmonary artery by gentle dissecti011 using microdissecting forceps. 
The J-reflector of a 2.5SB series ultrasonic flow probe (zero offset W d m i n ,  absolute 
accuracy *IS%), which was used to measure cardiac output (CO), was implanted around 
the ascending aorta and a small piece of surgical absorbable hemostat was placed 
between the 1-reflector and the right-anterior vena caw. Then, the chest was closed by 
using 4-0 sutures and the animal was weaned &om the respirator. The flowprobe cable 
was m e I e d  subcutaneously and the connector was exited at the back of the neck. 
2 3 3  Implantation of the radiotelemetric device 
Before implantation of the radiotelemetry capsule, the zero of each transducer 
was verified to be = *4 mrnHg. The catheter of a telemetry device was inserted into the 
left femoral artery and advanced so that the tip of the catheter was in the abdominal 
aorta above the iliac bhat ion .  After experiments, some rats were sacrificed to verify 
the position of the tip. The tip of the catheter was in abdominal aorta and below the r e d  
arteries. The capsule containing the traasducer and radiotransmitter was positioned in the 
left flank region subcutaneously. 
2.23 Cannulation of the femoral vein 
The left and right femoral veins were mulated with MRE040 tubing, which 
had been filled with 0.9% NaCl. The k e  ends of the catheters were tunneled 
subcutaneously and emerged at the back of neck. The ends of the tubing were then 
connected to a chronic cannula fashioned with a L-shaped 23G connector embedded in 
damn mesh with dentaI cement. The cannula was fixed subcutaneously and plugged 
with a 23G obturator. These catheters were used for infusions. 
23 Experimental protocols 
23.1 General 
10 days after surgeries, these rats regained their body weights h m  the loss of 
surgery. BP and CO were recorded m conscious, mestmined rats. Individual rat cages 
were placed on receivers (RLA 1020, Data Science) for recording of BP. Pressare data 
were collected with a computer driven data acquisition system (Dataquest IV, Data 
Sciences). The pressure wavefonn was sampled every 30 seconds with a 5-second 
sample duration. CO was recorded by feeding the signal fiom the flowmeter ('I206 
Transonic Systems Inc.) to a pen recorder (Grass Instrument Co. Quincy, MA). Mean 
CO was recorded continuousiy. TPR was calculated as the quotient of BP and CO. Two 
days before the recording, these rats were conditioned in the recording room. On the day 
of tbe experiment, a 2-hour control period was given before any drug infusion. 
233 ET dependent component in DOCA-satt hypertension 
2.3.2.1 Responses to a am-selective ET antagonist 
After a 2-hour control period, a bolus dose of bosentan (30 mg&g) or vehicle 
(distilled water) was injected into the femoral vein of both DOCA-salt hypertensive rats 
and SHAM-rats. These rats were recorded for another 3 how continuously. The 
bosentan infused DOCA-salt hypertensive rats were then recorded 24-hour later to 
monitor the time course of the recovery. The dose of bosentan used here had been tested 
to produce a maximum inhibition of ET-I induced pressor responses (BdaIcrishnan et al, 
1996; Clozel et ai. 1 994). Bosentan was dissolved in distilled water just before each 
experiment. 
23.2.2 Responses to a selective ETA antagonist 
After a 2-hour control period, a bolus dose of BMS-182874 (100 pmoYkg) or 
vehicle (5% NaHCa) was injected into the femoral vein of both DOCA-salt 
hypertensive rats and SHAM-rats. These rats wete recorded for another 3 hours 
continuousIy. The BMS- 182874 idbed DOCA-saIt hypertensive rats were then 
recorded for the next 3 consecutive days to monitor the time course of the recovery. The 
dose of BMS-182874 used here has been tested to produce a maximum inhiiition of 
ET-1 induced pressor response (Webb et al. 1995; Bird et al. 1995). 
233 AVP dependent component in DOCA-sdt bypertemion 
2.3.3.1 Effectiveness of bosentan 
To affirm bosentan, a mixed non-peptide ET antagonist, used in this study was an 
active and competitive antagonist at 100 minutes after its injection, the relationship 
between doses of ET-1 and responses elicited by this peptide in the presence and absence 
of bosentan was studied, Bosentan (30 mgkg) or vehicIe (distilled water) was infused 
intravenously in DOCA-salt hypertensive rats (n=6) and SHAM-conml rats (n=6). 100- 
min later, bolus doses of ET-1 at 0.03,0.06,0.1 and 0.3 moVkg were injected 
intravenousIy in a cumulative fashion every 10 minutes. The tespooses to ET-1 in the 
presence and absence of basentan in each anirnaI were separated by 3 days in a cross- 
over design. 
2.3.3 -2 Effectiveness of [~(cH&', 0-~e-~y8,Arg~]-~aso~ressin 
To affirm [ ~ ( C H Z ) ~ ' ,  0-~e-~y8,Arg~]-~aso~ressin, a VI receptor antagonist, 
used in this study was active and a competitive antagonist of AVP, the relationship 
between doses of AVP and hernodynamic responses in the presence or absence of the VI 
receptor antagonist wss studied. [~(cH&', 0-~e-~y8,Ar~~]-~asopressin (8 pgkg 
followed by 0.05 pg/kg/min) or saiine was infused intravenousIy in DOCA- and SHAM- 
rats. 30-min later, AVP at doses of 1,3,10 and 30 ng/kg/min was b h e d  through 
another femoral vein catheter for 10 min. in a cumulative graded fashion every 10 min.. 
These responses to AVP in the presence and absence of the V1 receptor antagonist in 
each animal were separated by a 2-day interval in a randomized cross-over fashion. 
In section 2.3 -3.1 and 2.3.3.2 studies, DOCA-salt hypertensive rats were treated 
with DOCA and salt for 2 weeks before surgical intervention, instead of 3-week's 
DOCA and salt pretreatment in the rest of the experiments reported in this thesis. 
2.33.3 Sequential antagonism of ET and AVP 
After a 2-hr control period, a single dose of bosentan (30 mgkg) was injected 
intravenously to both DOCA- and SHAM-rats. 100-mi. later, a bolus dose of 8 pg/kg of 
[~(cHz)~' ,  ~ - ~ e - ~ ~ ~ ~ ] - v a s o ~ r e s s i n  was injected a d was foIlowed by a 0.05 
pg/kg/min infusion. The 100-min period after bosentan was chosen because the response 
to bosenm had reached a plateau by this time (see section 3.1.2 and Fig. 1). The 
response to the VI receptor antagonist was recorded for another 30 min. 
In another group of animals, the sequence of the ET and AVP antagonists was 
reversed. After a 2-hour control period, the V1 receptor antagonist (8 p@kg followed by 
0.05 pg/kg/rnin) was administered intravenously to DOCA- and SHAM- rats. Thirty 
minutes later, a bolus dose of bosentan (30 rnglkg) was injected through another venous 
catheter. Responses were recorded for another 100 min. 
23.4 ET dependent component of AVP in DOCA4t hypertension 
2.3.4.1 Responses to AVP 
One hutldted minutes after an intravenous injection of bosentan (30 mgkg) or 
vehicle, single doses of [~r~"]-vaso~ressin (AVP) were infused intravenously at rates of 
1,3,10 or 30 ng/kglmin for 15 mia Only one of these four doses of A W  was selected 
for each rat, and 6-10 DOCA- or SHAM-rats were used for each dose. The selection of 
the dose was randomized and the responses to A W  in the presence or absence of 
bosentan were separated by a 4-day internal in a crosssver design. The 100-mi. period 
after bosentan was chosen because the response to bosentan in DOCA-rats had reached 
the plateau by this time. 
2.3.4.2 Responses to Ang II 
This protocol was identical to that for AVP, except that Ang EI was infused at 
rates of 3,9,30 or 90 ng/kg/min for 10-min, 
2.4 Data analysis 
All values are expressed as mean SEM. Graphs of the residuals were plotted to 
detect heterogeneity of variances. If needed, homogeneity of variances was achieved by 
log transformation of the data P values of less than 0.05 were considered statistically 
signiscant. 
2.4.1 ET dependent component in =A-salt hypertension 
Contrul values in both DOCA- and SHAM-groups were compared by analysis of 
variances (ANOVA) based on contrasts. Changes in BP, CO and TPR to bosentan or 
BMS-182874 and vehicle were performed by two-factor ANOVA (time and treatment). 
2.4.2 AVP pressor component in DOCA-salt hypertension 
Control values in both strains and effects of different treatments were compared 
by repeated-measuremeats of one (treatment or time) or two fktors (time and treatment) 
ANOVA. 
2.43 ET dependent component of AVP in DOCA-salt hypertension 
Responses to each dose of AVP in the presence or absence of bosentan within the 
DOCA- or SHAM-group was compared by ANOVA for repeated meamcement. 
Responses to AVP between these two p u p s  was analyzed by one-htor ANOVA. 
3. Results 
3.1 ET dependent component in DOCA-salt hyperteasion 
3.1.1 Control values 
Table 1 and 2 show the control values for BP, CO and TPR in DOCA-saIt 
hypertensive rats and SHAM-rats treated with bosentan and BMS-182874 respectively. 
BP was significantly higher in DOCA-salt hypertensive rats than in SHAM-rats. The 
elevated BP appeared to be due to elevated systemic resistance, as TPR was significantiy 
increased in DOCA-salt hypertensive rats. The values for CO were not significantiy 
different in the two groups. 
3.1.2. Responses to bosentan 
The time-course of the changes of BP, CO, and TPR evoked by bosentan are 
depicted in Figures 1,2, and 3. In DOCA-salt hypertensive rats, bosentan significantIy 
decreased BP (Fig. I) and TPR (Fig. 3) and increased CO (Fig. 2) compared to the pre- 
infusion control values and to the vehicIe control values. Significant depressor effects 
were observed at 30 min and the fall in pressure reached a plateau between 90 - 180 
minutes. Twenty-four hours later, all variables had returned towards control values. In 
contrast to the DOCA-salt group, the hernodynamic changes in the SHAM-group were 
unremarkable (Fig. 1,2 and 3). 
Table I. Control values in the bosentan treatment group 
Values ( means + sem ) for blood pressure @P), c d a c  output (CO) and total peripheral 
resistance (PR) in SHAM-operated rats (SHAM-rats) and DOCA-salt hypertensive rats 
(DOCA-rats) before bosentan treatment (3 determinations in each rat). Vc0.05 
compared to SHAM-rats. 
lo 4 T vehicle 
Time (min) 
F i r e  I. Changes in blood pressure (BP) in DOCA-salt hypertensive rats @OCA-rat) 
and sbam-control rats (SHAM-rat) evoked by i-v. injections of bosentan and vehicIe at 0 
time. *P<0.05 compared to 0 values, tPc0.05 compared to vehicle controIs. 
-. .- bosentan 
*t *t *t + vehicle 
I 
- 
Time (min) 
F i r e  2. Changes in cardiac output (CO) in DOCA-salt hypertensive rats OCA-rat) 
and sham-control rats (SHAM-rat) evoked by i.v. injections of bosentan and vehicle at 0 
time. *P<0.05 compared to 0 controIs, tP4.05 compared to vehicIe controls. 
-$-. vehicle 
T 
0 
*t 
I 
Time (min) 
Figure 3. Changes in total peripheral resistance (TPR) in MXA-salt hypertensive rats 
OOCA-rat) and sham control tats (SHAM-rat) evoked by i.v. injections of bosentan 
and vehicle at 0 time. V 4 . 0 5  compared to 0 values, tP<0.05 compared to vehicle 
controls. 
3.13 Responses to BMS-182874 
The changes of BP, CO and TPR are showed in Figure 4,5 and 6. In DOCA-salt 
hypertensive cats, BMS- 182874 sigdicantly decreased BP (Fig. 4) and TPR (Fig. 6) 
compared to pre-Wion control vaIues and to vehicle controls, The significant 
hypotensive effect of BMS-182874 started at 45 min after its infusion and lasted more 
than 24 hours. CO was elevated compared to vehicle control but this effect of the ET 
antagonist was small (Fig 5). The changes in BP, CO, and TPR returned to control 
values within 48-72 hours. Tn contrast to the WA-sal t  group, the hemodynamic 
changes in the SHAM-group were unremarkable (Fig. 4,5 and 6). 
Table 2. Control vdues in the BMS-182874 treatment p u p  
VaIues ( means f sem ) for blood pressure (BP), cardiac output (CO) and total peripheral 
resistance (TPR) in SHAM-operated rats (SHAM-rats) and DOCA-salt hypertensive rats 
(DOCA-rats) before BMS-182874 treatment (3 determinations in each rat). *P<O.OS 
compared to SHAM-rats. 
+ BMS-182874 
+ vehicle 
Time (min) 
Figure 4. Changes in blood pressure (BP) in DOCA-salt hypertensive rats @OCA-rat) 
and sham control rats (SHAM-rat) evoked by i.v. mjections of BMS-182874 and 
vehide at 0 time, *P4).05 compared to 0 d u e ,  tP4.05 compared to vehicIe control. 
vehicle * 
T 
Time (min) 
Figure 5. Changes in cardiac output (CO) in DOCA-salt hypertensive rats (DOCA-rat) 
and sham-controi rats (SHAM-rat) evoked by i.v. injections of BMS-182874 and 
vehicle at 0 time. *P<0.05 compared to 0 values, tP4.05 compared to vehicle controIs. 
1 + vehicle 
Time (min) 
Figare 6. Changes in total peripheral resistance (TPR) in MXA-salt hypertensive rats 
@OCA-rat) and sham control rats (SHAM-rat) evoked by i.v. injections of BMS- 
I82874 and vehicle at 0 time. *P<0.05 compared to 0 d u e s ,  tP4.05 compared to 
vehicie conaots. 
3.2 AVP dependent component in DOCA-salt hypertension 
3.2.1 Effectiveness of bosentan 
3 2.1.1 Control values and effects of bosentan 
Control values of BP, CO and TPR in DOCA- and SHAM- rats are shown in 
Table 3. Before bosentan, BP was significantly higher in DOCA-salt hypertensive rats 
than in SHAM-control rats. This elevated BP appeared to be due to the increased TPR, 
as the values for CO were not signiscantly different. In contrast to SHAM-control rats, 
bosentan lowered BP in DOCA-salt hypertensive rats at 100-min after its administration. 
32.1.2 Responses to ET-1 
The changes in BP, CO and TPR in DOCA-salt hypertensive rats and SHAM- 
control rats to cumulative i.v. injections of ET-1 in the presence or absence of bosentan 
are depicted in Fig, 7,s  and 9. ET-1 induced dose-related increases in BP and TPR, and 
the vasoconstriction was associated with a decrease in CO. The pressor responses 
induced by bwer doses of ET-1 were exaggerated in MXA-rats compared to SHAM- 
rats (Fig. 7), and the elevated pressor effect was due &y to the significantly increased 
vascular resistance, i.e., increased TPR (Fig. 9). Bosentan pretreatment attenuated the 
changes in BP, CO and TPR to ET-1 in both groups of rats. 
Table 3. Controt values for effectiveness of bosentan 
n=6 
Parameter Control Bosentan 
Values ( means + sem ) for blood pressure (BP), cardiac output (CO) and total peripheral 
n=5 
Control Bosentan 
TPR (mmHg/mVmin/kg) 00.73M.02* t 0.56iO.04 
resistance (TPR) in SHAMsperated rats (SHAM-rats) and DOCA-salt hypertensive rats 
0.54kO.04 0.49iO.02 
(DOCA-rats) before and 100-min after bosentan treatment. *P<0.05 compared to 
SHAM-rats and tP<0.05 compared to bosentan treatment. 
ET receptors blocked 
Figure 7. Changes in blood pressure (BP) to cumulative i.v. injections of ET-I before 
(ET-receptors functional) and after bosentan pretrwltment (ET-receptors blocked) in 
DOCA-salt hypertensive rats (DOCA-rat) and sham control rats (SHAM-rat). *PQ).OS 
compared to ET-1 with bosentan. tP<0.05 compared to SHAM-rats. 
ET receptors blocked 
Figure 8. Changes in cardiac output (CO) to cumulative i.v. injections of ET-1 before 
(ET-receptors functional) and after boserztan pretreatment (ET-receptors blocked) in 
DOCA-saIt hypertenjive rats (DOCA-rat) and sham control rats (SHAM-rat). *P<0.05 
compared to ET-receptors blockade. 
-e- ET receptors blocked 
2.5 1 + ET receptors hctioonal *t 
F i i  9. Changes in total peripheral resistance (TPR) to cumulative i.v. injections of 
ET-1 before (ET-receptors functional) and after bosentan pmreatment (ET-receptors 
blocked) m DOCA-At hypertensive rats -A-rat) and sham-control rats (SHAM- 
rat). *PQ3.05 compared to ET-receptors bIockade and tPG.05 compared to SHAM-rat. 
322.1 Control values and effects of the VI antagonist 
Control values of BP, CO and TPR in DOCA- and SHAM- were shown in Table 
4. Before the V1 receptor antagonist treatment, BP was significantly higher in DOCA- 
salt hypertensive rats than in SHAM-control rats. This elevated BP appeared to be due to 
the increased TPR, as the values for CO were not significantly different. The VL receptor 
antagonist failed to induce significant hernodynamic changes in both groups. 
3.2.2.2 Responses to AVP 
Changes in BP, CO and TPR in DOCA-salt hypertensive and SHAM-control rats 
to curnuIative i.v. infusions of AVP in the presence or absence of the V1 receptor 
antagonist are depicted in Fig. 10,ll and 12. AVP evoked dosedependent increases in 
BP and TPR, and decreases in CO in both strains. AVP failed to exert exaggerated 
pressor responses in DOCA-rats compared to SHAM-rats (Fig. 10). However, the 
increase in TPR to the lowest dose of AVP in DOCA-rats was significantly higher than 
in SHAM-rats (Fig. 12). Pretreatment with the VI receptor autagonist abolished these 
changes in BP, CO and TPR evoked by AVP. 
Table 4. Control values for effectiveness of [~(cH&', ~ - ~ e - ~ y ? ~ ~ ] - ~ a s o ~ r e s s i n  
Values ( means f sem ) for blood pressure (BP), cardiac output (CO) and total peripheral 
resistance (TPR) in SHAMsperated rats (SHAM-rats) and DOCA-salt hypertensive rats 
@OCA-rats) before and 30-min after the V I receptor antagonist (V ant.) treatment. 
*P<0.05 compared to SHAM-rats. 
Parameter Control V1 ant. 
BP (mmHg) 1356*  13e6 
CO (mVmin/kg) 197*13 195kll 
TPR (mmHg!mVminflcg) 0.7W.06* 0.71a.05 
Control Vl am 
l 1 l*2 1 1 1*4 
218i26 218i28 
0.55M.08 0.54M.08 
,- Vl receptors blocked 
AVP (ag/kg/min) 
Figure 10. Chaages of blood pressure (BP) to cumulative i-v. infUsions of AVP without 
(VI receptors firnctional) and with the VI antagonist pretreatment (Vt receptors 
blocked) in DOCA-salt hypertensive rats @OCA-rat) and sham control rats (SHAM- 
rat). *P<O.OS compared to the Vt antagonist pretreatment group. 
V1 receptors blocked 1 
AVP (ng/kg/min) 
1 * 
-120 + V1 receptors fimctional 
Figure 11. Changes in cardiac output (CO) to cumdative i.v. infkions of AVP without 
(VI receptors functional) and with the Vl antagonist pretreatment (V1 receptors 
blocked) in DOCA-salt hypertensive rats (DOCA-rat) and sham control rats (SHAM- 
rat). *P<0.05 compared to the VI antagonist pretreatment pup. 
0 
-20 - 
-40 - 
-60 - 
-80 - 
-100 - 
-120 - 
I I 
1 
* 
27 t Vl receptors blocked 
'1 + V1 receptors functioaal 1.5 * w 
Figure 12. Changes of total peripheral resistance (TPR) to cumulative i.v. idbions of 
AVP without (V1 receptors functional) and with the VI antagonist pretreatment (VI 
receptors blocked) in DOCA-salt hypertensive rats @OCA-rat) and sham control rats 
(SHAM-rat). *P91.05 compared to the VI antagonist pretreatment group and tP4.05 
compared to SHAM-rats. 
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3.23 Reeiprocrrl compensatory roles of AVP and ET-1 
3 23.I Control values 
Control values of BP, CO and TPR in DOCA-salt hypertensive and SHAM- rats 
in this study are shown in Table 5. BP was signitlcautly higher in DOCA-rats than in 
SHAM rats. This elevated BP appeared to be due to the increase in TPR, not to the 
factors regulating CO. 
3 2.3 2 Roles of AVP and ET 
The time-course of the changes in BP, CO and TPR in DOCA-salt hypertensive 
and SHAM- control rats treated with bosentan followed by the VI receptor antagonist are 
shown in Fig. 13, [n contrast to SHAM-control rats, bosentan significantly decreased BP 
and TPR in DOCA-salt hypertensive rats. After the blockade of ET receptors, the V1 
antagonist lowered BP and TPR below the levels achieved by bosentan done: the vaiues 
recorded during the 15-min infusion of the VI receptor antagonist were significantly 
lower than those recording at the 100-min mark. In SHAM control rats, the combhation 
of the two antagonists lowered BP and TPR significantly, but these changes were small. 
The changes in CO were unremarkable. 
The time-course of the changes in BP, CO and TPR in DNA-salt hrpeTtensive 
and SHAM-rats mated with the Vt receptor antagonist followed by bosentan are 
depicted in Fig. 14. In the first 30411 period, the V1 antagonist done did not elicit 
si@cant changes in BP, CO and TPR in either MXA-saIt hypertensive rats or 
SHAM-contml rats. After the blockade of Vl receptors, bosentan significantly lowered 
BP and TPR compared to the 0-min control dues and to its preinfusion values (at the 
30-min mark) in DOCA-salt hypertensive rats. In SHAM-rats, the combination of the 
two antagonists lowered BP si@cantly but only at the 130-min mark and the change 
was small. 
Comparison of effects of the VL receptor antagonist with and without blockade of 
the ET system in DOCA-salt hypertensive and SHAM rats are depicted in Fig. 15 and 
16. The Vr receptor antagonist alone failed to induce signiscant changes in BP and TPR 
However, with the pretreatment of bosentan, the V1 receptor antagonist decreased BP 
and TPR significantly compared to its preinfirsion values in DOCA-salt hypertensive 
rats. 
The effect of bosentan with and without btockade of VL receptors in DOCA-salt 
hypertensive and SHAM tats are showed in Fig. 17 and 18. Even in the absence of the 
V, receptor antagonist, bosentan lowered BP and TPR in the DOCA-sait hypertensive 
rats. However, the magnitude of these changes induced by hsentan was much greater 
when the rats were pretreated with the VI receptor antagonist. 
Table 5. Control values in bosentan and the V1 antagonist treatment study 
CO (drninflrg) 
TPR (rnmHg/mVmin/kg) 
18643 185*1 0 
0.86t0.05* 0.61id.03 
Values ( means + sem ) for bIood pressure (BP), cardiac output (CO) and total peripheral 
resistance (TPR) in SHAM-operated rats (SHAM-rats) and DOCA-salt hypertensive rats 
(DOCA-rats). *P<O.OS compared to SHAM-rats. 
F i  13. Timecourse of the changes in BP, CO and TPR of DOCA-salt hypertensive 
and SHAM rats treated with bosentan (Bos.) foilowed by the Vi antagonist (V1-ant). 
*p<O.OS compared to O-rnin values; WO.05 compared to dues at the start ofthe V1- 
anL(ie 100-min). 
F i  14. Tie-course of the changes in BP, CO and TPR of MXA-salt w e  
and SHAM rats treated with the VI antagonist (V~a t . )  followed by bosentan (Bos.). 
*p<0.05 compared to 0-min vaIues, W4.05 compared to values at the start of Bos. (ie. 
30-min). 
+ V1 ant. with ET receptors functional 
lo 1 _t Vl ant. with ET receptors blocked 
Figure 15. Changes in blood pressure (BP) in SHAM- or DOCA-salt hypertensive rats 
treated with the VI antagonist with (V1 ant. with ET receptors blocked) and *out 
bosentan (VI ant. with ET receptors fimctiond) pretreatment. *P<O.O5 compare to the 
initiai vaiue. 
Fig~re 16. Changes in total peripheral resistance (TPR) in SHAM- or DOCA-salt 
hypertensive rats treated with the V1 antagonist with (Vl ant, with ET receptors 
blocked) and without bosentan (Vr ant. with ET receptors fimctional) pretreatment 
*P<0.05 compare to the initid value. 
0.1 - + V1 ant. with ET receptors functional 
V1 ant. with ET receptors blocked 
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Figure 17. Changes in blood pressure (BP) in SHAM- or DOCA-salt hypertensive rats 
treated with bosentan with (Bos. with Vl receptors blocked) and without the VI 
antagonist (BOS. with V1 receptors fimctional) pretreatment. *P<O.05 compare to initial 
values; tP<O.OS compare to the effects of bosentan done. 
"' 1 + Bos. with V receptors hctional 
Bos. with VI receptors blocked 
Fire 18. Changes in totd peripheral resistance (TPR) in SHAM- or DOCA-saIt 
hypertensive rats treated with bosentan with (Bos. with VI receptors blocked) and 
without the VI antagonist (Bos. with VI receptors fimctional ) pretreatment. *P<O.OS 
compare to initid vdues; tP4.05 compare to bosentan treatment done. 
3 3  ET dependent component of AW in DOCA-salt hypertension 
33.1 Control values and effects of bosentm 
Control values of BP, CO and TPR in DOCA-salt hypertensive and SHAM- 
control rats before and after bosentan are shown in Table 6 for the AVP experiments and 
Table 7 for the Ang fl experiments. In both series before bosentan, BP was significantly 
higher in DOCA-salt hypertensive rats than in SHAM-control rats. This elevated BP was 
due to the increased TPR, as the values for CO were not significantly different. Bosentan 
lowered BP in DOCA-salt hypertensive rats at I00 min after its injection. This effect was 
exerted at the level of resistance vessets and not on factors regdating CO, as TPR was 
decreased. 
33.2 Responses to AVP 
The hernodynamic responses to AVP in DOCA-salt hypertensive and SHAM-rats 
in the presence or absence of bosentan are shown in Fig. 19,20 and 21. AVP induced 
dose-dated increases in BP (Fig. t 9) and TPR (Fig. 211, and decreases in CO (Fig. 20). 
In the absence of bosentan, changes in TPR to aU four doses of AVP were 
exaggerated in DOCA-rats compared to SHAM-rats (Fig. 21). Although the changes in 
BP evoked by AVP also tended to be higher in DOCA-sait rats than in SHAM rats, these 
differences were not statistically different (Fig. 19). 
Treatment with bosentan blunted the hmws in TPR evoked by AVP in both 
DOCA-salt and SHAM rats at I, 3 and 10 ng/kg/min (Fig. 21). This blunting effect was 
more dramatic in the DOCA-salt group. Consequently, the enhanced vascular 
responsiveness of DOCA-salt hypertensive rats to AVP observed when the ET system 
was functional was abolished in bosentan treated anhnals. Treatment with bosentan also 
attenuated the increases in BP evoked by AVP in both DOCA-salt and SHAM rats, at 
least at the 3 and 10 ng/kglmin doses. The effect of bosentan on CO was unremarkable. 
Tabk 6: Control values before and after bosentan pretreatment in AVP study 
Parameter 
BP 14W*t 126s 
d g  
CO 18&5 20 1 6  
m y d g  
TPR 0.83&0.04* 1 0.64i0.03 
mmHg/mVmin/kg 
n=32 
Control Bosentan 
Values ( means f sern ) for blood pressure (BP), cardiac output (CO) and total peripheral 
n=33 
Control Bosentan 
resistance (TPR) in SHAM-operated rats (SHAM-rats) and DOCA-salt hypertensive rats 
@OCA-rats) before and 100 min after bosentan treatment *P<0.05 compared to 
bosentan treatment and tP<O.OS compared to SHAM rats. 
80 1 --:-, ET-receptors functional 
ET-receptors blocked 
& 
AVP (nglkgimin) 
F i r e  19. Changes in blood pressure to AVP in the presence (ET receptors blocked) 
and absence (ET receptor fimctiond) of bosentan in DOCA-salt hypertensive and 
SHAM rats. *P<0.05 corn@ to the responses to AVP with bosentan pretreatment. 
AVP (ngkglrnin) 
0.1 1 10 100 
0 
+ ET-receptors functional 
-20 - 
- -+ ET-receptors blocked 
-40 - 
-60 - 
Figure 20. Changes in cardiac output to AVP in the presence (ET receptors bIocked) 
and absence (ET receptor fimctionai) of bosentan in DOCA-salt hypertensive and 
SHAM rats. 
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Figure 21. Changes in total peripheral resistance to AVP in the presence (ET receptors 
blocked) and absence (ET receptors fimctiond) of bosentan in DOCA-saIt hypertensive 
and SHAM rats. *P<O.OS compared to AVP responses with bosentan pretreatment and 
tPc0.05 compared to SHAM-rats- 
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0.6 - 
0.3 - 
T 
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3 3 3  Responses to Ang 11 
The hernodynamic responses to Ang I1 in DOCA-salt hypertensive and SHAM 
rats in the presence or absence of bosentan are shown in Fig. 22,23 and 24. Ang I1 
induced doserelated increases in BP (Fig. 22) and TPR (Fig. 24), and decreases in CO 
(Fig. 23). 
In the absence of bosentan, changes in TPR and BP to 3,9 and 30 ng/kg/rnin of 
Ang II were exaggerated in DOCA-rats compared to SHAM-rats (Fig. 24 and 22). 
Treatment with bosentan faded to changes the responses to Ang 11 in both 
DOCA-salt and SHAM rats. Consequently, vascdar and pressor responsiveness to Ang 
II remained elevated in the DOCA-salt hypertensive rats. 
3.4 Comparison of control values 
All control values in the previous three studies h m  DOCA-salt and SHAM- 
control rats, which had been m e d  for 3 weeks, are shown in Table 8. BP and TPR were 
significantly higher in DOCA-salt rats than in SHAM rats. There were no significant 
difference among values for each parameter in these three studies both in DOCA-salt 
hypertensive and SHAM-controI groups. 
Table 7: Conml values before and after bosentan pretreatment in Ang II study 
n=25 
Parameter Control Bosentan 
Values ( means k sem ) for blood pressure (BP), cardiac output (CO) and total peripheral 
n=26 
Control Bosentan 
BP 1 55*2* t 134G 
m m g  
CO 1 9 W  205*8 
mY*g 
TPR 0.84M.O3*t 0.6e0.04 
mmHg/ml/minflrg 
resistance (TPR) in SHAMsperated rats (SHAM-rats) and DOCA-salt hypertensive rats 
103*1 9&2 
19&5 203*8 
0.5W.02 0.51iO.02 
@OCA-rats) before and 100 min after bosentan treatment, *P<0.05 compared to 
bosentan treatment and iP<0.05 compared to SHAM-control rats. 
--@-- ET-receptors blocked 
Ang II (ng/kg/min) 
Figure 22. Changes in blwd pressure to Ang II in the presence (ET receptors blocked) 
and absence (ET receptors hctional) of bosentan in DOCA-salt hypertensive and 
SHAM rats. +P<O.OS compared to Ang II responses in SHAM rats in absence of 
bosentan and Y<O.OS compared to SHAM rats in presence of bosentan. 
Ang II (mg/kg/min) 
F i r e  23. Changes in cardiac output to Ang II in the presence (ET receptors blocked) 
and absence (ET receptors hctional) of bosentan in DOCA-salt hypertensive and 
SHAM rats. 
+ ET-receptors functional 
ET-receptors blocked 
T 
Figure 24. Changes in totaI peripheral resistance to Ang lI in the presence (ET receptors 
blocked) and absence (ET receptors fimctional) of bosentan in DOCA-salt hypertensive 
and SHAM rats. tP<0.05 compared to Ang II responses in SHAM rats in absence of 
bosentan and P<0.05 compared to SHAM rats in presence of bosentan. 
Table 8: Comparison of control values: 3-week's treatment 
DOCA-rats I SHAM-rats 
BP CO TPR I BP CO TPR 
(mmHg/ml/min/kg) in DOCA-salt hypertensive and SHAM-control rats in a11 three 
Study I 
Study II 
studies of this thesis work. *P<0.05 compared to SHAM-tats. 
141W 174i8 0.84iO.04* 
' 154W 186H 0.86H.05* 
1 0 4 s  185+8 0.57H.03 
low 185f 10 0.61M.03 
104e 1 9 1 6  0.57fi.02 study m 
Contml values (meanksern) for BP (mmHg), CO (mVmin/kg) and TPR 
153~* 188fi 0.84H.04* 
4. Discussion 
The experiments reported in this thesis were performed in conscious unrestrained 
rats. By recording BP with radiotelemetry devices and CO with chronically implanted 
flowprobes, hernodynamic variables could be recorded for prolonged periods without 
restraint and in a relatively stress-free environment, Because of problems in maintaining 
externalized arterial catheters patent, including problems associated with kinking and 
clotting, externalized catheters are typically implanted only 24 h before experiments are 
initiated. With telemetry implants, the instrumentation of the animals could be 
completed 10 days before beginning the experiments, and BP could be recorded for 
prolonged periods afterwards. This 10-day period served to allow a full recovery of the 
animals and to condition them in the recording environment. 
The DOCA-salt model of hypertension was chosen for study. This model was 
derived h m  a lminqhrectomized SD rat treated with DOCA and salt water, while the 
norrnotensive control rat was the uninephrectomized SD rat, The DOCA-salt 
hypxtensive model is characterized as AVP and ET dependent, a RAS independent and 
volume overload form of hypertension (see section 12). It is the model representing 
human hypertension with chronic mineraIocorticoid excess, such as adrenal adenoma, 
1 IS-hydroxylase deficiency etc. (Weber et al. 1995). 
4.1 Control values 
4.1.1 BP recording and its interpretation 
BP recorded with radiotelemetric devices in 3-week DOCA-treated hypertensive 
rats in aII the studies ranged fiom 1 4 U  to 1556 mmHg. These values were lower than 
those reported to occur: values ranged 6om 157*6 to 1716 d g  when pressure was 
recorded h m  chronically implanted externalized catheters (Wang et aI. 1993; Wang and 
McNeiU, 1994). The differences were not due to errors in either of the methods because 
BP recorded by both methods simultaneously in the same animal yielded similar values 
at all time points in a validation study done in our lab (Balakrishnan et al. 1998). The 
lower BP measured by radiotelemetry in DOCA-salt hypertensive animals p d e l s  
previous works done by us and others in SHR (Balakrishnan et al. 1998; B a d  et al. 
1993). The reason for lower BP in hypertensive animals recorded with radiotelemetry is 
unclear. It may be related to a lower level of stress and/or the longer recovery and 
conditioning period associated with this method (10-day's recovery with radiotelemetry 
vs. 1 day's recovery with external catheters). Indeed, a major advantage of telemetry is 
that BP can be recorded both acutely and chronically for weeks and months in conscious 
animals with less intervention, 
The elevated BP baseline values associated with either the tail cuff method or 
externd catheters may, in turn, affect the magnitude of responses to pharmacological 
interventions. Indeed, BaIakn'shnan et at. compared responses recorded with 
radioteIemetry to those recorded with e x t e m h d  catheters. They found pressor 
responses to infusions of AVP were diminished while antihypertensive responses 
accompanying withdrawal of AVP were exaggerated when BP was recorded with 
externalized catheters in SHR (BaIahishnan et al. 1998). Similarly, Bazil et a1 reported 
that the antihypertensive effect of captopril recorded by externalized catheters or by the 
tail cuff method disappeared when BP was recorded by radiotelemetry devices ( B a d  et 
al. 1993). These results emphasize the importance of baseline BP values in q u a n w g  
responses to hypertensive or hypotensive agents and, consequently, the telemetry system 
in BP recording in animal research, 
4.12 Resistance responses: importance of CO measurement 
In this thesis, CO was measured with the ultrasonic transit-time system 
(Transonic). In contrast to electromagnetic flowmeters which have uustable zero 
baselines, and Doppler flowmeters which measure veIoci~, but not volume flow, 
Transonic flowmeters measure volume flow wit& stable zero baselines. In addition, one 
of most important features of the Transonic ff owmeter is that it is relatively insensitive to 
vessel dimensions, flow profile, and flow turbulence. This flow measurement technique 
is a reliable and accurate method for recording flow in response to vasoactive agents in 
both acute and chronic experiments (Xavier et aI. 1996; Wen et al. 1996). 
Flow measurements are critical for evaluating vascular responses to vasoactive 
agents. Since BP is determined by CO and TPR, one cannot assume that changes in BP 
reflect changes in the resistance function of the circdation. Rather one must calculate 
resistance fiom flow and pressure recordings. Furthermore, BP is an insensitive index of 
vasoconstrictor activity, because an hcrease increase TPR is o h  associated with a fill in CO 
which attenuates the increase in BP. Indeed, AVP induces an increase in mesenteric 
vascular resistance and TPR at piasma concentrations within the physiological range, but 
this vasoconstrictor activity is not expressed as a change in BP because of a fd in CO 
(Montani et al. 1980; Martin and McNeill, 1987; Martin and McNeiU, 1988). This is 
consistent with the findings reported in this thesis. The increases in TPR induced by 
exogenous AVP were exaggerated in DOCA-salt hypertensive rats compared to changes 
in TPR in SHAM rats (Fig. 21), while changes in BP were not significant difference in 
the two p u p s  (Fig. 19). These results emphasize the value of flow recording in 
evaluating the responses of resistance vessels. 
TPR was calculated as an index of the resistance function of the circulation in 
this thesis. In regional vascular studies in vbo, changes in vascular tone induced by 
vasoactive agents often result in changes in regional blood flow without much changes in 
BP, a consequence of the parallel arrangement of the various regional beds. In this case, 
vascular conductance, the inverse of resistance, is IinearIy related to flow and is a proper 
index to reflect changes in vascular tone unless a constant flow prepmion is used 
(Lautt, 1989; h t t  and McQuaker, 1989). Indeed, in this situation, conductance can 
only dectease to zero while resistance can increase to infinity. In systemic vascuIar 
studies, vasoactive agents can induce changes in both CO and BP. Ifa drug evokes a 
proportionally gteater effm on BP than on CO, then TPR, which is diredy proportional 
to BP, is the appropriate calculation. Accordingly, TPR was seIected as an index to 
reflect changes in systemic vascular tone in this thesis, because ET receptor antagonists 
induced greater changes in BP than in CO in 00CA-salt hypertensive rats, and the non 
peptide mixed ET receptor antagonist, bosentan, was involved in all three studies 
reported in this thesis. 
In all studies (Table 1- 7); BP control values were higher in DOCA-salt 
hypertensive rats than in SHAM rats. The elevated BP was due to a significant increase 
in TPR in this hypertensive model as there was no significant differences in CO between 
these two groups. The results are consistent with the notion that high blood pressure in 
established hypertension is due mainly to an increase in peripheral vascular resistance 
(Vanhoutte and Liischer, 1986). 
4.2 ET dependent component 
4.2.1 Responsivenas to bosentan and BMS-I82874 
Bosentan and BMS-182874 evoked f d s  of arterial pressure in DOCA-salt 
hypertensive rats, but not in SHAM-control rats. The large decreases in BP induced by 
the non-selective and selective ETA receptor antagonists indicate that the ET system, 
most likely through the ETA receptor, conmiutes to the maintenance of hypertension in 
this DOCA-salt hypertensive model, The findings on the effects of a non-selective ET 
and a selective ETA receptor antagonist on BP are consistent with those reported by 
others in the DOCA-salt model (Li et al. 19% Doucet et aL 1996; Stein et al. 1994). 
The characteristics of bosentan and BMS-182874 and their specificities are well 
documented (Clozel et al. 1994; Stein et al. 1994; Webb et d. 1995). Bosentan is a 
mixed ET antagonist which blocks both E& and ETB receptors with a half-life of 5 to 8 
hours in human (Ubeaud et al. 1995), while BMS-182874 is a selective ETA receptor 
antagonist. Both of them are water-soluble and are unlikely to cross the blood brain 
barrier. Judging liom the long-lasting hypotensive effect in DOCA-salt rats compared to 
bosentan, BMS-182874 may have a Longer half-life than bosentan. The pattern of the fall 
in pressure evoked by bosentan was similar to that by BMS-182874 (Fig. 1 and 4). Thus, 
the predominant role of endogenous ET in the DOCA-saIt model is vasoconstriction, 
which is apparently mediated at least in part by ETA receptors. This contrasts with the 
normotensive rat, in which the vasodilator effect of ETe receptors appears to dominate 
(Gellai et al. 1996). 
A major finding reported here is that tbe BP Iowering effect of bosentan and 
BMS-182874 in the DOCA-saIt hypertensive rats was exerted at the level of the 
resistance vessels. TPR was higher in this group (Table I), and bosentan and BMS- 
182874 decreased TPR markedly in these hypertensive animals (Fig. 3 and 6). Our 
findings on TPR are consistent with the findings reported by others on the effects of the 
ET antagonist, bosentan, on regional vascular resistance (Doucet et al. 1996). In 
contrast to TPR, the increases in CO tended to oppose the BP lowering properties of 
bosentan and BMS-182774. The increase in CO was Iikely a consequence of the 
decreased afterload resulting from the vasodiIatot effect of ET antagonists. This study 
appears to be the first reporting data on the changes of TPR and CO to non-selective and 
selective ETA receptor antagonists in conscious DOCA-saIt hypertensive rats. 
In contrast to the DOCA-saIt model, bosentan and BMS-182874 had little effect 
on BP in normotensive rats. Some investigators have reported that the mixed ET 
antagonist, bosentan, or selective ETA receptor antagonists, BQ123 and FR139317, 
slightIy but significantly reduced BP in normotensive rats (Doucet et al. 1996; Bigaud 
and Pelton, 1992; Fujita et al. 1999, while others reported that BQlU failed to change 
BP (Bazil et aI. 1992). These differences may be related to the experimental conditions 
such as the state of anesthesia (Pollock and Opgenorth, 1993), a stress-related 
component (Bazil et d. 1W3), or genetic diversity of animaIs (Nabika et al. 1991). In 
our lab, we monitored BP in conscious unrestrained rats with radioteIemetry devices, a 
technique that appears to be associated with lower stcess (Bazil et al. 1993), and found 
that bosentan and BMS-182874 fail to induce changes in BP in normotensive rats 
(BaIakrishnan et al. 1996; Balakrishnan et al. 1997; Yu et at. 1998). These results 
indicate that endothelin is not essential for the control of BP in the normotensive rat. On 
the other hand, GeUai et al. found no evidence for a contn'bution of ETA receptors to 
vascular tone in normotensive rats, but they did observe a significant vasodiIator role for 
ETe receptors (Gellai et al. 1996). Clearly, the relative contribution of ETA and ETe 
receptors appears to differ in the hypertensive and nomotensive rat. 
4.23 Vascular responsiveness to ET-1 
In the DOCA-sait hypertensive rat, ET-I content in blood vessels is elevated 
(Lariviere et al. 1993b) ttnd the increases in BP and TPR to the lower doses of ET-1 were 
enhanced compared to SHAM-contd rats (Fig. 7 and 9). These d t s  are consistent 
with the notion that the vasopressor effect of ET conmiutes to the maintenauce of 
vascular tone in this hypertensive animal model. Changes in vascular concentration of 
ET-1 result in changes in its receptors' functions. Indeed, ET receptors are 
downregulated and ET- 1 had been shown to evoke decreased contractile responses of 
aorta and mesenteric artery rings in this hypertensive animal (Nguyen et al. 1992). 
However, the hernodynamic response to ET-1 was enhanced in this study. In fact, the 
magnitude of the increases in TPR is due not only to the direct vasoconstrictor effect of 
ET-I but also to the structural changes of resistance vesseIs observed in hypertensive 
animals (see section 4.4.1). 
In summary, these data suggest that the ET system contriiutes to the maintenauce 
of high BP and vascular tone via its vasopressor effect in DOCA-salt hypertensive rats. 
The maintenance of high blood pressure is exerted primarily at the level of the resistance 
vessels and not on factors that regdate cardiac output. Finally, the hemodynamic 
changes recorded with the mixed ET antagonist, bosentan, are similar to those observed 
with the selective ETA antagonist, BMS-182874, suggesting that ETA receptor fuaction 
accounts for much of the blood pressure elevating properties of ET, at least in DOCA- 
salt hypertension. 
4 3  AVP dependent component 
43.1 Relationship of AVP and ET in maintenance of BP 
Administration of the VI antagonist alone failed to change BP, CO and TPR (Fig. 
14). There are controversial reports regadng the effect of a V1 receptor antagonist on 
BP in DOCA-salt hypertensive rats (see introduction 12.1). This discrepancy may be 
attributed to experimental conditions, such as anesthesia and surgicd intervention 
associated with acute experiments (McNeilI and Pang, 1982; Bonjour and Malvia, 
1970), or stress-related components, such as  BP measured by tail-cuff or externalized 
catheters associated with chronic experiments (Bad  et al. 1993; Balabrrishnan et al. 
1998). Indeed, both plasma concentration of AVP and BP were increased shortly after 
surgery (McNeill and Pang, 19821, and the BP-lowering eff' of captopril was 
exaggerated in rats when BP was recorded by either the tail clrffmethod or the use of 
externalized catheters (Bazil et d. 1993). h addition, most of the previous reports were 
studied in DOCA-salt hypertensive rats with malignant hypertension (Crofton et al. 
1979; Hiwatari et al. 1986; FiIep et aI. 1983, which is associated with severe 
complications. In this study, BP and TPR were monitored in conscious and unrestrained 
rats with established, but not malignant, hypertension. BP was recorded with 
radiotelemetry devices which allowed a long recovery period before beginning 
experiments (at least 10 days). Under these condition, we found that the V receptor 
antagonist alone failed to induce any signiscant changes in BP and TPR in DOCA-salt 
hypertensive rats. The dose of the VL receptor antagonist used here had been shown to 
block responses to AVP in both DOCA-salt hypertensive rats and SHAM-control rats 
(Fig. 10 and 12). 
The faiiure of the V1 receptor antagonist alone to induce hernodynamic changes 
in DOCA-salt hypertensive rats W I e  4 and Fig. 14) does not exchde a role for these 
receptors in the maintenance of BP and TPR in tbis hypertensive animal model. The 
importance of AVP may be underestimated when only one system is the object of study. 
Indeed, the Vt receptor antagonist significantly decteased BP and TFR in DOCA-salt 
hypertensive rats after the blockade of the ET system Fig. 13, 15 and 16). This 
hptensive effect of the Vl receptor antagonist was not likely due to any delayed action 
of bosentan because responses to bosentan had reached a plateau by this time (see 
section 3.1.2 and Fig. 1 and 3 ). These results suggest a mle of AVP in the maintenance 
of hypertension in tbis experimental hypertensive rat. The observation that the VI 
receptor antagonist induced hemodynamic changes in DOCA-salt hypertension only after 
the blockade of ET system suggests that the ET system compensates to maintain blood 
pressure when the VI receptors were blocked. 
Conversely, it appears the AVP system compensates in responses to blockade of 
the ET system in order to support blood pressure because the hemodynamic changes to 
bosentan were exaggerated in this hypertensive animal in the presence of the Vl 
antagonist (Fig. 14, 17 and IS). Together, the data obtained from the two series of 
experiments in which the AVP system and ET system were bIocked sequentially reveal 
the reciprocal or redundant nature of the ET and AVP systems in maintenance of 
systemic hernodynamics in DOCA-salt hypertensive rats. In the absence of one system, 
the other compensates M y ,  and it is only when both systems were the object of study 
that the importance of each became evident. Thus, the Wure of an antagonist to reduce 
BP must be interpreted cautiously. 
Interestingly, bIockade either of AVP or ET receptors alone did not induce any 
significant changes in BP and TPR in SHAM-conaol rats (Table 3 and 4, Fig. 13 and 
24). This observation suggests that ET and AVP are not essential in maintenance of BP 
in these normotensive tats. However, when these nomotensive rats were treated with 
both bosentan and the V1 receptor antagonist concurrently, BP and TPR decreased 
significantly, although the changes were smd (Fig. 13 and 14). These r d t s  finher 
demonstrate a reciprocal relationship between the ET system and AVP systems. 
In summary, the synergetic effects of bosentan and the VI receptor antagonist 
suggest that the ET and AVP systems are overlapping mechanisms that play a reciprocal 
role in the maintenance of systemic hernodynamics in conscious DOCA-salt 
hypertensive rats: when one system is inhiiited, the other compensates to maintain it. 
43.2 Effectiveness of bosentan and [d(~&);, ~-~e-~ylf&]-vaso~ressin 
The doses of bosentan and [~(cH*)~', 0-~e-~y8,Arg~]-vaso~ssin were chosen 
h m  the Literature. Nevertheless, in order to prove that the compounds in our possession 
were active, we tested their ability to block the responses evoked by ET-1 and AVP. The 
dose-related increases in BP and TPR evoked by ET-1 in both DOCA-sdt and SHAM 
rats were markedly attenuated by bosentan (Fig. 7 and 9). The dose-related increases in 
BP and TPR evoked by AVP in both =A-salt and SHAM rats were virtually 
abolished by [~(cH&', o - M ~ - T ~ ? , A ~ ~ ~ ] - v ~ s o ~  (Fig. 10 and 12). 
4 3 3  Baselint effect of bosentan to ET-1 
It could be argued that the effects of bosentan on responsiveness to ET-I were 
influenced by different baseline valws. Bosentan caused a marked reduction in TPR and 
BP in DOCA-salt hypertensive rats, and the dose-response relationships to ET-I in the 
presence of bosentan were recorded h m  this Iower baseline compared to the response in 
the absence of bosentan. However, this effect of bosentan done should, if anything, 
exaggerate responses to ET-1 since a lower baseline leaves a greater potential for a 
vasoconstrictor or pressor response. Indeed, there is data to show that a lower basehe 
tends to exaggerate pressor responses (Balakrishnan et al. 1998) and to diminish 
depressor responses ( B d  et al. 1993; Baialnishnan et al. 1998). Thus, if anything, the 
effectiveness of the blockade with bosentan wodd be uadefestimated by the baseline 
effect. 
1.4 Contribution of ET to AVP evoked responses 
44.1 Vascular responsiveness to AVP and Ang I1 
Vascular responsiveness to AVP appeared to be enhanced in DOCA-salt rats at 
least as judged by the changes in TPR: the increases in TPR evoked by AVP were greater 
in DOCA-salt hypertensive rats than in SHAM control rats (Fig. 21). This hding on 
vascular reactivity, together with the fact that plasma AVP is increased in this 
hypertensive rat model (Mohring et al. 1977; Crofton et al. 1979), provide additional 
evidence implicating AVP in maintenance of vascular tone in DOCA-salt hypertensive 
rats. 
In contrast to the data shown in Fig. 21, the data shown in Fig. 12 suggests that 
except for the lowest dose of AVP, vascular responsiveness to AVP was not enhanced in 
the DOCA-saIt group compared to SHAM rats. However, the data in Fig. 12 were 
derived h m  a cumulative dosage design in 2-week DOCA-salt animals compared to the 
single dosage design in 3-week DOCA-salt rats for the data reported in Fig. 21. These 
differences might be related to experimental protocols (a SingIedose infusion vs. 
infUsions in a cumulative fashion) andlor the severity of hypertension (3-week vs. 2- 
week's DOCA and salt treatment). Indeed, Matsuguchi and Schmid did find that the BP 
responses to AVP were related to the duration of the hypertensive regimen in the DOCA- 
salt animal (Matsuguchi and Schmid, 1982). In the final analysis, the data on single 
infUsions in the 3-week's DOCA-salt treated hypertensive rats would be seem to be the 
more relevant. 
While changes in TPR to AVP were enhanced in this hypertensive r* changes in 
BP were not enhanced. This result fUrtber emphasizes the importance of TPR monitoring 
to evaluate hernodynamic responses to a vasoactive agent. The reason that the changes in 
vascular reactivity were not translated into changes in pressor activity are unknown, but 
may be related to a specific enhancement in baroreflex activity associated with elevations 
in the circulating levels of AVP in the DOCA-salt hypertensive animal (see section 
1.1.1.12). 
VascuIar responsiveness to Ang II was also enhanced in DOCA-salt hypertensive 
rats: the changes in TPR evoked by Ang II were greater in DOCA-salt hypertensive rats 
than in SHAM control rats. In DOCA-salt hypertensive rats, plasma renin activity is 
markedly lower and vascular Ang I1 receptors are upregulated (Schiffrin et al. 1983). 
This increased receptor density could contriiute to the enhanced vascular 
responsiveness. In contrast to AVP, the enhanced v d a r  responsiveness was expressed 
as an increase in pressor responsiveness. This finding is pethaps not surprising since Ang 
II does not enhance baroreflex activity. Indeed, it may attenuate reflexes (Guo and 
Abboud, 1984). 
Similar to AVP and Ang 11, vascular responsiveness to ET-1 was aiso enhanced 
in DOCA-salt hypertensive rats. This enhanced responsiveness was associated with 
enhanced pressor responsiveness, at least at the two lower doses of ET-I (Fig. 7 and 9). 
The observation that vascular tesponsiveness was enhanced to all these peptides, 
AVP, ET-1 and Ang II, suggested that the increase in vascular reactivity is non-specific. 
Responsiveness to vasoactive agents depends not only on its interaction with receptors, 
but also on the vascular structure of resistance vessels. Folkow et al (Folkow et a]. 1973; 
Folkow, 1982) proposed that the augmented vascular reactivity in hypertension is due a 
decrease in the lumen to wall thickness ratio of resistance vessels. Thickening of the 
arteriolar wall occurs due to hypertrophy or hyperplasia of vascular smooth muscle &Is 
in the media of blood vessels. Indeed, vascular hypertrophy is very severe in resistance 
arteries fhm DOCA-salt hypertensive rats, with a prominent thickening of the media 
@eng and SchBh ,  1992). The remodeled resistance arteries &%it a reduced 
circumference, which acts as an amplifier to vasoconstrictor activity. This stnrcturalIy 
based amplification may explain the difference between the enhanced TPR responses 
observed in viva in this study and the attenuated contractile effect to ET-I reported to 
occur in blood vessels rings preparation (Nguyen et al. 1992). These attenuated 
contractile responses to ET-1 in vitro might be ampIified by the vessel remodeling, 
resuIting in normal or augmented pressor responses in vivo. 
In contrast to Ang II and ET-1, the enhanced vascular responses to AVP were 
not expressed as an increased pressor responsiveness. In fact, pressor responsiveness to 
AVP is complex and it is buffered by increased baroreflexes and decmsed CO which 
might offset any non specsc structurally-induced enhancement of vascular 
responsiveness (see introduction 1.1.1.2) 
4.4.2 Contribution of ET to the hernodynamic effects of A W  
The blunted responsiveness of both DOCA-salt hypertensive and SHAM conml 
rats to AVP in the presence of bosentan (Fig. 19 and 21) is the major finding in this part 
of the thesis (Result 3.3). The data here provide direct evidence at the hernodynamic 
level that ET conmiutes to the pressor activity of AVP in this hypertensive animal 
model and its normotmive control. For reasons discussed earlier (see section 4.3.3), the 
magnitude of the contribution of ET was likely underestimated in the hypertensive group 
because bosentan lowered BP in this group (126 vs. 149 mmEfg in Table 6) providing a 
greater potential for a BP elevating response to AVP in the bosentan treated hypertensive 
animals. 
The observation aIso demonstrates that this contniution of ET to the pressor 
activity of AVP is exerted at the level of resistance vessels, as TPR responses to AVP 
were decreased when the ET system was blocked (Fig. 21). in contrast, deaemes in CO 
tended to oppose the BP elevating effect resulting fhm the vasoconstrictor activity of the 
peptide, and bosentan failed to change CO respnses to AVP (Fig. 20). 
The data is consistent with work demonstrating release of ET-1 by AVP. AVP 
has been shown to increase ET-I reIease in cultured endothelid cek, h m  perfused 
mesenteric arteries, and in a whole animal study (Emori et al. 199 1 ; Tomobe et al. 
1993a; Emmeluth and Bie, 1992). In addition to reIease of ET-1, ET-i gene expression 
and ET-1 content of blood vessels are eIevated in DOCA-salt hypertensive rats (Lariviere 
et al. 1993b; Lariviere et al. 1993a), and chronic treatment with OPC-21268, a VI 
receptor antagonist, attenuated the enhanced ET-1 gene expression in this hypertensive 
model (Intengan et al. 19%). Finally, plasma levels of AVP are elevated in the DOCA- 
salt animal model (Mohring et al. 1977; Yamamoto et al. 1984; Filep et al. 1987). 
Accordingly, it is reasonable to postulate that AVP contributes to the hypertensive state 
indirectly by increasing ET-1 gene expression and by releasing ET-1. 
Similar to DOCA-salt hypertensive rats, ET also contributed to the changes in 
TPR evoked by AVP in SHAM control SD rats. The contribution was more profound in 
DOCA-salt hypertensive rats than in S W  rats (Fig. 21). By contrast, ET did not 
contribute to the hemdynamic responses to AVP in a different normotensive strain, 
namely WKY rats (Balakrishnan et al. 1997). This discrepancy in normotensive rats 
might be caused by the strain difference, WKY vs. SD rats. Indeed, the pressor response 
to AVP was significantly higher in SD rats than in WKY rats (Tatchum-Talom and 
McNeill, 1997). 
The concIusions of this study depend on the assumption that bosentan is a 
selective ET antagonist, and dso that the dose empIoyed would antagonize the ET 
system in DOCA-salt hypertensive rats and SHAM control rats to a similar extent. The 
pharmacological characteristics of bosentan have been desmibed in detail by Clozel et a1 
(Clozel et al. 1994): the compound competitively inhibited the specific binding of ET-1 
to a variety of cell types, but Wed to affect the binding of 40 other peptides including 
AVP. Moreover, the dose of bosentan used in this study has been tested to attenuate tbe 
effects of ET-I in both rat groups (Fig. 7 and 9). 
In contrast to AVP, bosentan failed to blunt the increases in BP and TPR elicited 
by Ang II both in DOCA-salt hypertensive rats and SHAM control rats (Fig. 22 and 24), 
suggesting that the contribution of ET to the hernodynamic responses to AVP may be 
specitic in this hypertensive model. There ae conmverslerSlal reports regarding the effect 
of Ang II on ET-1 secretion from cuItured cells (Emori et aI. 1991; Hieda and Gomez- 
Sanchez, 1990; Essig et al. 1997). The reason for this is unknown. It might be due to the 
origin of cells, i.e. h m  Merent tissues or h m  diffetent species. In vivo, Emmeluth 
and Bie reported that -on of AVP, but not Ang I& increased pIasma ET-I leveIs in 
conscious dogs m e l u t h  and Bie, 1992). However, Balakrishnan et al. from our lab 
showed that bosentan significantly blunted pressor responses to lower doses of Ang II 
both in SHR and WKY rats (Bd- et al. 1996), indicating the involvement of ET 
in the responses to Ang a. The differences in the involvement of ET in the hemodynamlc 
responses to Ang II between DOCA-salt hypertensive rats and SHR may be related to 
plasma renin activity, humoral factors, andlor genetic diversity. 
In summary, the results suggest that ET c a n t n i  to the hernodynamic effects 
of AVP, but not Ang II, m both DOCA-saIt hypexmsive rats and SHAM-controUed SD 
rats. This contniution is exerted at l e d  of the resistance fimction ofthe circulation, and 
not on fixtors that regdate CO. 
4 5  Conclusion and Summary 
The roles of the ET system and AVP system, and the interaction between these 
systems in maintenance of systemic hexnodynamics of DOCA-salt hypertensive rats and 
SHAM control rats were examined in experiments descn'bed in this thesis. BP was 
recorded with the radiotelemetry, a technique which is associated with Iowa level of 
stress and which is suitable both for acute and chronic experiments. CO was monitored 
with the Transonic system, which measures volume flow, instead of flow velocity. Using 
these techniques, we were able to record BP and CO in conscious d e d  rats 10 
days after recovery h m  surgery and for 2 weeks afierwards. 
In contrast to SHAM-controUed rats, bosentan, a mixed ET antagonist, and BMS- 
182874, a selective ETA antagonist, lowered BP dramatically in the DOCA-saIt 
hypertensive animal. This hypotensive effect of ET antagonists was due to a decrease in 
TPR not to factors regdating CO, since CO was increased by ET antagonists. The 
magnitude and time-course profile of the hypotensive propties of bosentan and BMS- 
182874 were similar. These findings suggest that the contriiutian of ET can be 
accounted for by its effects on ETA receptors located on resistance vesseIs of the 
circulation. 
Administration of the Vl receptor antagonist done failed to induce sigdicaut 
changes in DOCA-salt hypertensive rats and SHAM-controlled rats. However, the V[ 
receptor antagonist decreased BP and TPR signiscantIy when the ET system was 
blocked and prevented from compensating in this hypertensl've animal. Conversely, the 
responses to bosentan were significantly exaggerated after the blockade of VI receptors 
compared to the responses to bosentan alone in the DOCA-salt hypertensive animal. 
These results demonstrate the involvement of AVP in maintenance of systemic 
hemodynamics via its vasoconstrictor effects mediated by VI receptors, and also reveal 
the reciprocal or redundant relationship between the AVP system and ET system in the 
control of systemic hemodynamics in the DOCA-salt hypertension. 
In contrast to Ang 11, the vasopressor responses to AVP were blunted by bosentan 
both in DOCA-salt hypertensive rats and SHAM-controlled rats, but more profoundly in 
the former. This provides direct evidence at hexnodynamic level for an ET component 
contributing to the pressor responsiveness to AVP. The contribution of ET to pressor 
activity of AVP was exerted at the level of the resistance vessels, not on factors which 
regulate CO. 
In conclusion, the results of this thesis demonstrate the involvement of both the 
ET system and AVP system, and the reciprocal or redundant nature between these two 
systems in the control of systemic hemodynamics in DOCA-salt hypertensive rats. The 
resdts also demonstrate a contribution of ET to pressor activity of AVP in DOCA-salt 
hypertension. 
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